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Abstract 
Hepatitis C virus (HCV) infects at least 3% of the global population , 80% of 
those will develop chronic HCV infection, which can lead to liver scarring and 
hepatocellular carcinoma. Natural killer (NK) cells provide a rapid defense 
against viral infections, thus, evasion of NK cell functions may be key for the 
establishment of viral persistence and chronic infection. Here, we show that 
HCV-infected cells directly interact with, and dampen NK cell cytokine and 
cytotoxic functions , independent of cytopathic effects exerted by HCV infection of 
the human hepatoma cells. We observed no change in expression levels of NK 
cell activating receptors , NKG2D, NKp46 or CD16 on NK cells exposed to HCV-
infected cells , nor of human histocompatibility-linked leukocyte antigen (HLA)-E 
on HCV-infected compared to uninfected cells . However, surface expression of 
the natural cytotoxicity receptor NKp30 was reduced and infection of Huh-7.5 
cells with HCV increased surface binding of an NKp30-lgG1 Fey fusion protein , 
suggesting up-regulation of an antagonistic NKp30 ligand on HCV-infected cells. 
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1 Introduction 
1.1 Host Invasion, Immune Evasion 
Human immunity has been classically divided into innate and adaptive 
responses. The adaptive immune response has been characterized as being 
solely mediated by B and T cells, as progenitors of these lymphoid cells undergo 
recombination-activating gene (Rag)-dependent antigen-specific gene 
rearrangement to produce a diverse repertoire of antigen-specific receptors (1 ). 
Innate immunity is comprised of cells and mechanisms that recognize and 
respond to pathogens in a generic, non-specific manner, providing the first line of 
defense (2). Viral persistence is dependent upon successful evasion of host 
immune defenses. This coexistence of viruses and hosts induces evolutionary 
pressure on the host immune system as well as on viral genes, forcing viruses to 
develop ways to evade host recognition. 
Viral evasion strategies can include the synthesis of decoy proteins that 
inactivate immune responses, such as innate toll-like receptor (TLR) sensing (2). 
For example, hepatitis C virus (HCV) proteins, such as the non-structural protein 
3 (NS3) can facilitate evasion of the innate immune response through disruption 
of TLR adaptor molecules (3) . Viruses can also interact with and disrupt host 
humoral immune responses , via antigenic variation , and cellular immune 
responses and/or effector functions (2). Documented HCV evasion strategies 
1 
involve diminished type I interferon (IFN) responses (4-9), impaired cytotoxic 
cos+ T cell activity and suppression of CD4+ T helper (Th)1 responses (10). 
To escape the adaptive T cell response, viruses may also encode genes 
to produce proteins, termed immunoevasins, which ultimately prevent the cell 
surface display of viral peptides in complex with major histocompatibility complex 
class I (MHC-1) molecules forT cell recognition (2) . Although down-regulation of 
cell surface MHC-1 expression upon viral infection will impair T cell recognition , 
these cells would subsequently become sensitive to natural killer (NK) cell-
mediated lysis. To usurp NK cell recognition and function, viruses, such as 
human cytomegalovirus (HCMV), will encode proteins (i.e. UL 14 and UL 141) that 
retain ligands for NK activating receptors inside infected cells (11 , 12). 
As with HCMV, human immunodeficiency virus (HIV) also down-regulates 
MHC-1 surface expression upon infection , allowing HIV-infected cells to escape T 
cell recognition yet remain resistant to NK cell cytolysis (13) . HIV is thought to 
accomplish this through selective down-regulation of certain MHC-1 complexes 
while preserving those interacting with inhibitory NK cell receptors (14, 15). The 
emergence of protective NK cell killer immunoglobulin receptors (KIR) :MHC-1 
allelic combinations in the context of HIV infection also provides evidence that NK 
cells play a role in the control of early infection (16, 17). Recently, association 
studies have revealed HCV-infected individuals have a higher probability of 
spontaneous clearance with a certain combination of NK cell KIR and human 
2 
leukocyte antigen (HLA) alleles (discussed in Section 1.4) (18-22). Thus, 
observations from multiple studies of NK cells in the context of viral infections 
indicate that viruses can evade immune pressure by generating variants that 
modulate recognition of infected cells by NK cells. Here, we specifically consider 
the effects HCV-infected cells have upon NK cells. 
1.2 Hepatitis C Virus 
1.2.1 Hepatitis C Virus Infection 
HCV has been estimated to infect 3% of the world's population (23). In the 
absence of effective treatment, approximately 80% of individuals exposed to and 
infected with HCV fail to mount an immune response adequate for viral 
clearance, develop chronic infection , and suffer an increased risk of liver fibrosis 
and hepatocellular carcinoma (24-26) . Only 20-30% of individuals infected with 
HCV will spontaneously clear the virus. However, emerging evidence suggests 
that HCV ribonucleic acid (RNA) persists in serum at levels undetectable by 
currently used clinical assays (27). The mechanism by which HCV infection is 
spontaneously cleared is unknown, and a better understanding of both the 
clearance process and of viral strategies underlying immune escape is necessary 
for future vaccine development and management of infection. 
Currently, there are seven major genotypes of HCV that differ in their 
nucleotide sequence by 30-35% (28). Treatment efficacy varies with genotype, 
3 
genotype 1 being the least responsive to treatment. Prior to 2011 , combination 
treatment for HCV with pegylated interferon-alpha (peg-IFN-a) and ribavirin 
produced a sustained virological response (SVR) in 40-60% of genotype 1 
patients (reviewed in [29]). SVR can be improved to 60-80% for individuals 
infected with genotype 1 HCV with introduction of one of the recently Food and 
Drug Administration (FDA)-approved HCV NS3/4A protease inhibitors, telaprevir 
or boceprevir (30). Although these new treatments are promising , methods to 
limit the emergence of drug-resistant quasispecies and/or a prophylactic vaccine 
to prevent HCV infection are needed. 
1.2.2 Hepatitis C Virus Experimental Systems 
A non-A, non-B hepatitis virus was first identified and its eDNA cloned in 
1989 (31 ), however, efficient culture of HCV in vitro remained elusive. In 1997, 
Rice's lab discovered that the original HCV clone lacked the 3'-untranslated 
region (UTR) necessary for replication in cell culture, and subsequently produced 
a full-length functional eDNA clone (32, 33). The study of HCV replication in cell 
culture was made possible by Bartenschlager's group in 1999 following their 
development of the bicistronic HCV replicon system containing a neomycin 
resistance gene. Neomycin is expressed under the control of the HCV internal 
ribosome entry site (IRES), whereas the non-structural NS3-NS5B proteins are 
under the control of the encephalomyocarditis virus (EMCV) promoter, thereby 
allowing maintenance of HCV RNA following electroporation of the replicon into 
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the human hepatoma, Huh-7, cell line (34). The Huh-7 cell line was originally 
established from hepatoma tissue removed from a 57 -year old Japanese male 
with hepatocellular carcinoma (35). 
Progress in understanding the HCV life cycle and developing therapeutic 
interventions against this pandemic were also hampered by the lack of a small 
animal model. In 2001, Mercer et at. succeeded in developing chimeric 
human/murine livers by transplanting human hepatocytes into severe combined 
immunodeficient (SCID) mice harbouring an albumin-urokinase type plasminogen 
activator transgene (AL-uPA) (36) , a gene that encodes a serine protease 
involved in cell migration and tissue remodeling (37, 38). Targeting the liver with 
the AL-uPA transgene causes cytopathic effects in hepatocytes expressing AL-
uPA thereby allowing hepatocytes that do not express the transgene to 
repopulate the liver (39, 40). These transgenic mice develop HCV infection with 
high viral loads when inoculated with sera from HCV-infected individuals. 
Although this was the first small animal model for the in vivo study of HCV, 
it was not adequate for the study of innate or adaptive immune responses or 
pathogenesis . Prior to the development of the SCID/uPA murine model, 
chimpanzees were, and continue to be used for the in vivo study of HCV vaccine 
development and some aspects of innate and adaptive immune responses to 
HCV infection. Although they reproduce many characteristics of HCV infection in 
humans, such as protective CD4+ and CDS+ T cell responses to HCV infection 
5 
(41, 42), they are an endangered species and their use in medical research is 
strictly limited. 
The lack of both a small animal model to study in vivo HCV infection and 
the inability to reproduce the complete HCV life cycle in vitro hampered the 
examination of viral entry, assembly and general virus-cell interactions. The HCV 
pseudoparticle (HCVpp) system developed in 2003 by Bartosch and Cosset 
allowed the study of viral glycoprotein functions during entry (43). In the HCVpp 
system, recombinant retroviruses containing unmodified HCV glycoproteins are 
produced following co-transfection of plasmids encoding HCV E1/E2 proteins, 
retroviral Gag-Pol proteins, a packaging component and a retrovirus-derived 
reporter gene to detect infection into human 293T cells (43). It was not until 
2001 , 12 years after the discovery of HCV, that Kato and Wakita isolated an HCV 
genotype 2a clone from a Japanese patient with fulminant hepatitis (Japanese 
fulminant hepatitis 1, JFH-1) (44). This clone was capable of in vitro replication 
(45) in the permissive human hepatoma cell line, Huh-7.5, a subclone of Huh-7 
cells (46-48). More importantly, JFH-1 permitted the study of the complete HCV 
life cycle in cell culture for the first time, since genomes transfected into Huh-7.5 
cells transcribed and replicated the viral genome, assembled virions and released 
infectious HCV particles, termed HCVcc (cell culture-derived HCV) (46-49). 
Furthermore, HCVcc particles are capable of infecting HCV-susceptible animal 
models (47, 49). 
6 
1.2.3 Hepatitis C Virus Structure and Protein Functions 
HCV is an enveloped, positive-sense RNA virus of the Hepacivirus genus 
within the Flaviviridae family (3). The uncapped 9.6 kb RNA genome includes 5'-
and 3'-UTRs with the 5'-UTR being necessary for effective RNA replication and 
containing an IRES to mediate cap-independent translation (50, 51 ). The 5'-UTR 
is conserved among genotypes and is believed to be integral to the replication , 
stability and packaging of HCV RNA into intact particles (51). 
The HCV genomic RNA is translated into a polyprotein by the host 
ribosomal machinery and cleaved co- or post-translationally by host and vira l 
proteases to form structural proteins, which comprise the virus particle (core, 
envelope glycoproteins E1 and E2) , p7, and non-structural proteins (NS2, NS3, 
NS4A, NS4B, NS5A, NS5B) which aid in either virion assembly and/or viral 
replication (3, 46). Viral replication occurs within replication complexes (RCs), 
which are formed from altered endoplasmic reticulum (ER) membranes and 
contain viral and cellular proteins essential for viral replication (52). The HCV 
core multimers form the nucleocapsid in which the HCV RNA genome is 
encased. The nucleocapsid is surrounded by an envelope derived from ER 
membrane in which E1 and E2 are embedded (53) (Figure 1.1 ). 
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1.2.3.1 HCV Structural Proteins 
The structural proteins comprise the physical structure of the virus particle. 
This section will briefly discuss the known functions of each protein. 
1.2.3.1.1 HCV Core Protein 
Immature core protein stems from the N-terminus of the HCV genome and 
is cleaved by signal peptidase, and then further cleaved by signal peptide 
peptidase to yield a mature core protein of 21 kilodalton (kDa) (54). Mature core 
protein consists of two domains: a highly basic N-terminal domain (01) that 
associates with HCV RNA, and a hydrophobic C-terminal domain (02), which 
mediates an association between core and lipid droplets (LOs) (55). This core-
LD association is necessary for infectious HCV production , since abrogation of 
this interaction inhibits virus production (56, 57) . However, it is currently unclear 
whether capsid oligomerization and assembly occur on ER membranes or the LD 
surface (55, 57, 58). 
1.2.3.1.2 HCV E1 and E2 Glycoproteins 
Infectious HCV particles possess E1 (-35 kDa) and E2 (-70 kDa) 
glycoproteins embedded in a lipid bilayer surrounding the core nucleocapsid (59) . 
HCV envelope proteins are required for viral entry into host cells via interaction 
between E1/E2 and several host cell receptors (43). The N-linked glycosylated 
envelope glycoproteins are type I transmembrane proteins that form non-covalent 
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heterodimers on the virus particle (60). The N-terminus consists of the entry 
determinants for viral infection of host cells whereas the C-terminus is 
responsible for the heterodimerization of the glycoproteins and contains ER-
retention signals that may anchor the glycoproteins in the envelope (61 ). A major 
neutralizing epitope has been identified as the hypervariable region (HVR) 1 
located at the N-terminus of E2 (62 , 63). HCV entry is mediated through 
interaction with host scavenger receptor class B type I (SRBI) and domains I and 
Ill of CD81 (also termed target of antiproliferative antibody 1 [TAPA1]) (64, 65). 
Although it is thought that HCV E1 and E2 form heterodimers on the virus 
surface, the glycoproteins could undergo a pH-dependent conformational 
rearrangement to facilitate a fusogenic trimeric form as occurs with other 
Flaviviridae (i.e. dengue virus [DENV] or West Nile virus [WNV]) (61 , 66, 67). 
This trimeric conformation would expose the fusion tip , of which E1 is thought to 
be involved, enabling delivery of the HCV RNA genome into the cytoplasm of the 
newly-infected cell (3, 68, 69). 
1.2.3.1.3 HCV p7 Polypeptide 
The -7 kDa p7 polypeptide is found at the junction between the structural 
and non-structural proteins and is cleaved by host signal peptidase (3) . Although 
the precise structure and function of p7 have yet to be unequivocally determined, 
it is essential for HCV infectivity and may form homopolymeric complexes with 
ion channel capabilities (70) , similar to influenza virus M2 protein (71 ). In 
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addition, p7 may also contribute to viral assembly (72, 73) through interaction 
with other HCV proteins such as E1 and NS2. 
1.2.3.2 HCV Non-Structural (NS) Proteins 
The non-structural proteins are critical for viral replication and assembly 
but are not physical components of the virus particle. This section will briefly 
discuss the known functions of each protein. 
1.2.3.2.1 NS2 
Dimeric NS2 (-23 kDa monomer) is a transmembrane protein with C-
terminal cysteine protease activity responsible for self-cleavage of the protein 
from the adjacent NS3 (74, 75). NS2 is essential for virus assembly, though the 
mechanism by which NS2 acts during this process remains to be determined (76-
78). 
1.2.3.2.2 NS3 and NS4A 
Like NS2, the -70 kDa protein NS3 also catalyzes polyprotein processing. 
The N-terminal serine protease domain heterodimerizes with NS4A (16 kDa) to 
direct NS3 to the ER where, via serine protease activity, it cleaves the polyprotein 
boundaries between NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5A/NS5B (3). 
The C-terminal domain has RNA helicase and RNA-stimulated nucleoside 
triphosphatase (NTPase) activity (79) , which contributes to RNA unwinding and 
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also viral replication and assembly (80). NS4A co-localizes with RCs, supporting 
its professed role in viral replication (81 ). Jones et at. demonstrated an 
interaction between core and NS3 proteins that is essential for virus assembly 
(82). NS3 has also been shown to usurp host innate immune responses by 
cleaving important adaptor molecules (Section 1.1 ). 
1.2.3.2.3 NS48 
One of the lesser characterized HCV proteins is the highly hydrophobic 
NS4B (27 kDa), but it is believed to be an integral oligomeric membrane protein 
(83). Evidence suggests that NS4B induces ER membrane convolutions , 
commonly referred to as the 'membranous web ', forming RCs in concert with 
other viral and host proteins in order to support HCV RNA replication (52, 84). 
NS4B may contribute to Flaviviridae cytopathicity, however, the studies 
suggesting this were performed in the context of bovine viral diarrhea virus 
(BVDV) and remain to be confirmed in the context of HCV infection (85). 
1.2.3.2.4 NS5A 
The NS5A protein has varied interactions with other viral and cellular 
proteins involved in viral replication and assembly, has no known enzymatic 
activity, and is found at 56 kDa when hypophosphorylated or 58 kDa when 
hyperphosphorylated (3). The NS5A protein is a dimeric zinc-binding 
metalloprotein comprised of three domains (D) (86, 87) , with 01 being important 
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for cellular membrane attachment and containing the helix that interacts to and 
binds core at LD surfaces (88, 89). It is proposed that Dl and Dll contain RNA-
binding residues that aid both RNA replication (90-93) and the switch between 
viral translation and replication (94). Most recently, Dill has also been implicated 
as having low in vitro RNA binding capacity (95). The interaction between NS5A 
Dill and core protein has also been shown to be essential for viral assembly (96). 
In addition, the degree of NS5A phosphorylation is thought to balance viral RNA 
replication , as decreasing the hyperphosphorylation of NS5A tends to increase 
RNA replication (90, 92). 
1.2.3.2.5 NS5B 
Viral RNA replication is mediated through the catalytic subunit of the 
68 kDa NS5B protein , the RNA-dependent RNA polymerase (3). In comparison 
with other polymerases, HCV NS5B has the classical right hand structure 
complete with finger, palm and thumb domains with the active site between the 
finger and thumb domains (97-99) . Palm domain catalytic residues can align the 
RNA template strand and nucleotide triphosphates for transcription (1 00). 
1.2.4 Hepatitis C Virus Life Cycle 
Entry of HCV into permissive hepatocytes requires multiple host co-
receptors including CD81 (43, 101-104), SRBI (105-107) , occludin (OCLN) (108-
11 0) and claudin-1 (CLDN1) (111 , 112). The entry process, including cell 
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binding, clathrin-mediated endocytosis and low pH endosomal fusion , is mediated 
primarily by HCV E1 and E2, which interact with conserved residues with in both 
host SRBI (1 07) and the large extracellular loop (LEL) of tetraspanin CD81 (113-
116) (Figure 1.2) . Viral association with high density lipoproteins will enhance 
viral entry, providing there is adequate SRBI expression on hepatocytes (43, 117, 
118). High levels of SRBI receptors occur on hepatocytes and are important for 
the uptake of cholesterol from lipoproteins. The low density lipoprotein receptor 
(LDLr) also may be involved in viral entry through interaction with lipoprotein 
particles (3). Most recently, epidermal growth factor receptor (EGFR), ephrin 
receptor A2 (EphA2) and the Niemann-Pick C1-like 1 (NPC1 L 1) cholesterol 
uptake receptor have been identified as host cofactors for HCV entry (119, 120). 
In addition to CD81 and SRBI , CLDN1 expression and binding to HCV E2 is 
essential for viral entry into permissive hepatocytes (112). Moreover, Harris eta/. 
have demonstrated lateral CD81 :CLDN1 complexes are important for viral entry 
(121 , 122). 
Post-attachment, it is believed that HCV endocytosis occurs in a clathrin-
dependent process with successful entry and subsequent fusion dependent on 
adequate acidification of the endosome to trigger pH-dependent fusion (123) 
(Figure 1.3) . The open reading frame of the positive sense, uncapped HCV RNA 
genome is translated via the 5'-IRES by host machinery, and co- and post-
translationally modified by viral and host proteases to yield the 10 mature viral 
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proteins to enable negative RNA strand synthesis (3). Both host and mature 
HCV proteins localize to ER membranes to comprise RCs that replicate positive 
sense genomic HCV RNA into the negative strand template. Subsequently, 
positive sense HCV genomes are produced, translated into viral proteins and 
assembled into mature infectious virus particles (3). 
Although the precise mechanism by which HCV assembly occurs is 
unknown, it is thought that viral RNA and core protein accumulate on host LOs, 
possibly via a core:NS5A interaction (124). HCV E1 and E2 heterodimerize and 
migrate, along with p7, to the assembly site, possibly through NS2 interactions 
(125, 126). Viral capsids form and bud into the ER lumen in a manner that 
incorporates apolipoprotein E (55, 127) then mature into infectious particles. 
The very low density lipoprotein (VLDL) assembly pathway is thought to 
provide a means for viral maturation and egress, however, as with virus 
assembly, viral egress is also enigmatic. Data suggest that the release of 
infectious HCV particles relies on components of the endosomal sorting complex 
required for transport (ESCRT) pathway (128). Circulating mature virus particles 
released into the extracellular environment in HCV-infected individuals are 
complexed with VLDL (129, 130). This process and the ensuing host immune 
response are characteristic of liver disease. 
The progression of liver disease in those chronically infected with HCV is 
usually a process involving inflammation and deposition of collagen , which leads 
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to hepatocellular fibrosis and , in some instances, cirrhosis. Although HCV is not 
directly cytopathic, it can trigger host immune responses, such as cytokine 
production and hepatocyte apoptosis (reviewed in [131 , 132]). 
1.2.5 Hepatitis C Virus-Associated Cytopathic Effects 
In mammalian cells , flaviviruses cause cytopathic effects (CPEs) via 
apoptotic mechanisms. For example, DENV serotype 2 (DENV-2) and WNV NS3 
proteins (133-135) , as well as overexpression of HCV NS4A and/or NS4B have 
been implicated in causing CPEs, the latter likely from ER stress due to the 
membranous web and RC formation (85, 136, 137). Using a novel plaque assay, 
Sekine-Osajima eta/. demonstrated that JFH-1 replication results in large-scale 
cell death (138) . Subsequent mutagenesis studies by Mishima et a/. on HCV 
NS5A and NS5B showed that enhanced viral replication positively correlated with 
increased CPE (138, 139). Although preliminary, these findings may have 
implications for the development of liver steatosis, cirrhosis or hepatocellular 
carcinoma. 
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1.3 Natural Killer Cells 
1.3.1 Natural Killer Cell Innate and Adaptive Immune Responses 
Comprising 5-20% of peripheral blood lymphocytes, NK cells can be found 
enriched in liver and uterine tissues (140) , and provide inherent, tissue-resident 
defense against transformed cells and many pathogens, including viruses. 
Classically defined as cytolytic lymphocytes after their discovery in the 1970's 
(141 , 142), NK cells are categorized as innate immune effector cells as they do 
not undergo gene rearrangement, thus, recogn ize and target infected or 
transformed cells through a diverse assortment of germ-line encoded receptors 
(143) (Figure 1.4). NK cells have the innate capacity to recognize and ki ll target 
cells with down-regulated surface MHC-1 molecules, a process that occurs during 
many viral infections (143) . Although originally categorized as innate immune 
cells , it was recently suggested that NK cells demonstrate immunological 
memory, a feature predominately associated with adaptive immunity (144). 
There are four phases ascribed to cells of the adaptive immune system. In 
response to an encounter of a na"lve T cell with its cognate ligand, the pathogen-
specific T cell population proliferates and expands , resulting in effector cells (145, 
146). Following a period of effector activity, these activated T cells will undergo 
apoptosis, a phase termed 'contraction ' (147, 148). Stable, long-lived memory T 
cell populations (145, 146, 149) will remain in both lymphoid and non-lymphoid 
22 

TIM-3 
CD 56 
FcyRIII NKp46 
(CD16) 
NKp44 CD160 
24 
NKG2D 
NKG2A/CD94 
tissues (150, 151) to provide defense against previously encountered pathogens. 
In response to an encounter with their cognate antigen, memory T cells enter the 
final phase and undergo a robust expansion against antigenic challenge (152). 
Although not extensively documented, recent evidence suggests that, like 
adaptive immune cells , some NK cells can generate memory cells against 
previously-encountered haptens or pathogens after initial exposure (144). Using 
the murine cytomegalovirus (MCMV) infection model, Sun et at. documented NK 
cells undergoing clonal-like expansion, persisting in lymphoid and non-lymphoid 
tissues, and then mediating a more efficacious effector function response upon 
re-encounter with the same virus, all traits of the adaptive immune response 
(153, 154). A similar response has been noted in human studies revealing that 
Hantavirus, HCMV and HIV infections result in increased circulating NKG2C+ NK 
cell subsets (155-157). The precise mechanisms by which NK cells develop and 
maintain immunological memory remain to be determined , but it appears to 
involve selective expansion of NK cells with a particular receptor repertoire in 
response to antigenic challenge . 
1.3.2 Natural Killer Cell Functions 
T cell immune responses mediate long-term control of viral infections; 
however, management of these infections by NK cells prior to the onslaught of 
the adaptive immune response is crucial. In humans, sensitivity to viral infections 
is associated with depressed NK cell functions (158). Of particular note, Biron et 
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a/. described the case of an adolescent female patient who had a genetic NK cell 
deficiency, a complete and specific lack of NK cells, functions, and inducible killer 
activity, presenting with an extreme sensitivity to herpes virus infections despite 
normal B and T cell numbers (159). Murine studies have also indicated that NK 
cell cytotoxicity and IFN-gamma (IFN-y) production critically contribute to the 
control of MCMV (160) , influenza (161, 162) and herpes simplex-1 (163) 
infections. Furthermore, not only are NK cells important for the early control of 
viral infections, but they also play a role in the induction of the adaptive antiviral 
immune response, through the release of immunomodulatory cytokines and 
chemokines (164) and through bidirectional interactions with dendritic cells (DC) 
(reviewed in [165] and [166]). This leads to the induction of type 1 IFNs and 
subsequent production of T h 1 cytokines driving the T cell response towards the 
T h 1 adaptive response and ultimately, a reduction in viral replication or clearance 
of viral infection ( 167). 
NK cells fall into two main functionally distinct subsets. The highly 
cytotoxic CD56dimCD16bright NK cells are considered more mature, while 
CD56brightCD16dim immature NK cells predominantly secrete pro-inflammatory 
cytokines, such as IFN-y, tumour necrosis factor alpha (TNF-a), and in some 
cases, the immunoregulatory cytokine interleukin (IL)-1 0 (13, 168). A recent 
study showed that CD56dim NK cells also produce large amounts of IFN-y 
promptly (2-4 hours) following activation (169). NK cells recognize altered cells 
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and carry out their cytotoxic functions through germ-line encoded receptors. The 
outcome of engagement of these receptors is determined through the balance of 
signals and interactions from NK cell inhibitory and activating pathways. 
The T cell immunoglobulin mucin-3 (TIM-3) receptor has recently been 
identified to elicit an inhibitory cytotoxic and cytokine response in NK cells when 
bound with galectin-9 (Gal-9) or phosphatidylserine (PtdSer) (170-175). Gal-9 is 
expressed on immune innate and adaptive cells and tissues , such as lymph 
nodes, thymus, bone marrow and spleen , and is abundant in liver tissues (174, 
176). Gal-9 is a soluble protein released from cells that cross-links cell-surface J3-
galactoside carbohydrate moieties to modulate cell signaling , adhesion , and 
survival (177, 178). Since Gal-9 recognizes certain carbohydrates, and NK cell 
receptors can vary in the glycosylation of their ectodomains, the extent of ligand 
recogn ition and binding may vary, thereby providing another level of control over 
NK cell functions (179-181 ). The phospholipid component of PtdSer is usually 
expressed on the cytosolic side of cell membranes, however, when a cell is 
induced to undergo apoptosis, PtdSer becomes expressed on the external 
surface of the cell membrane and can be recognized by TIM-3 and other 
receptors (175, 182, 183). 
Other inhibitory receptors , such as some KIR receptors or lectin-like 
NKG2AICD94 heterodimers predominantly recognize unaltered 'self' cells 
through their expression of MHC-1 complexes, which are expressed on nearly 
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every cell in vivo , thereby preventing cytolysis of healthy autologous cells (143) . 
As per the 'missing self' hypothesis, healthy cells expressing optimal amounts of 
MHC-1 complexes are less sensitive to lysis by NK cells than transformed or 
virus-infected cells with decreased MHC-1 expression (184) (Figure 1.5). Tumour 
and virus-infected cells expressing adequate amounts of MHC-1 molecules are 
actively inhibited from directed cell lysis, and this is one mechanism by which 
pathogens escape NK cell surveillance (Section 1.1 ). 
Intriguingly though , interaction of certain NK cell inhibitory receptors with 
MHC-1 ligands during NK cell ontogeny influences NK cell responses during 
ensuing receptor-ligand interaction. This process has been referred to as NK cell 
'licensing' and is crucial for NK cell maturation into fully functional licensed 
effector NK cells (185-187). Thus, the greater number of inhibitory receptors that 
recognize MHC-1 complexes NK cells have, the more responsive these cells will 
be towards cells lacking MHC-1 molecules. The enhancement of NK cell 
responsiveness following recognition of MHC-1 complexes by NK inhibitory 
receptors indicates the role these inhibitory receptors have is not straightforward. 
The acquisition of NK cell licensing via interaction of MHC-1 complexes with 
inhibitory receptors requires signaling through associated inhibitory motifs . NK 
inhibitory receptors can possess intracytoplasmic immunoreceptor tyrosine-based 
inhibitory motifs (ITIMs) , distinguished by a conserved cytoplasmic sequence of 
six amino acids (typically 1/L/SNxYxxLN, where x represents any amino acid) , 
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which become phosphorylated at the tyrosine residue, engaging Src homology 2 
(SH2) domain-containing protein phosphatases, SHP-1 and SHP-2 (188, 189). 
Stress and infection often result in reduced surface MHC-1 expression , 
thereby lessening inhibition and allowing NK cells to lyse altered target cells 
through stimulation of activating receptors, such as the natural cytotoxicity 
receptors (NCRs) NKp46, NKp44, NKp30 or NKG2D, and non-classical MHC-1 
HLA-E-specific NCRs CD94/NKG2C and CD94/NKG2E (143, 190-195). The 
NCR NKp44 is predominantly expressed on activated NK cells , whereas NKp30 
and NKp46 expression appears to be constitutive , with NKp46 being the only 
specific marker for NK cells (192, 196). A number of ligands have been identified 
for NK activating and inhibitory receptors , however, many are left to be identified. 
For instance, NCR NKp46 is thought to play a role in recogn ition of 
Mycobacterium tuberculosis (197) and NKp44 is implicated in binding 
components of bacterial cell walls (198) . Although it is believed that NKp46 
contributes to the NK cell response against tumour cells (199, 200) , tumour 
ligands for both NKp44 and NKp46 remain elusive. Known ligands for NCR 
NKp30 include transmembrane protein B7-H6, which is expressed on 
transformed cells , and nuclear factor HLA-B-associated transcript 3 (BAT3) , both 
of which activate NK cells (201 , 202) . Other known ligands, such as viral 
hemagglutinin (HA) and HCMV tegument protein pp65, prevent target cell lysis 
through NCR NKp30 (203, 204). The best characterized activating NK cell 
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receptor is the low-affinity receptor for immunoglobulin G (lgG) , CD16 (FcyRIII) , 
which recognizes antibody-coated cells and is responsible for antibody-
dependent cell-mediated cytotoxicity (ADCC) (Figure 1.6) (143). 
Although some NK cell activating receptors , such as CD160, associate 
with membrane-bound proteins (reviewed in [205]), most activating receptors 
contain adaptor molecules that associate non-covalently with the cytoplasmic 
receptor domain to initiate signaling cascades. Most adaptor proteins, such as 
DNAX-activating protein of 10 or 12 kDa (DAP1 0, DAP12) , FcyR, and the s chain 
contain at least one cytoplasmic immunoreceptor tyrosine-based activating motifs 
(ITAMs). CD16 and the NCRs NKp30 and NKp46 can associate with either FcyR 
or s chain homo- or hetero-dimers to mediate cell signaling, introducing an even 
greater level of NK cell functional complexity (206) (Figure 1.7). 
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1.4 Natural Killer Cells in Hepatitis C Virus Infection 
Epidemiological studies suggest NK cells play a role in determining the 
outcome of HCV infection (19, 207). Some biomedical studies indicate that 
although NK cell numbers are reduced in chronically infected individuals, NK 
activating receptor and cytolytic functions increase (18, 208) . Conversely, other 
studies reported decreases in NK cell activating receptor expression , IFN-y 
production and cytotoxic activity (140, 209, 210). Nattermann et a/. showed that 
in vitro activated NK cells derived from HCV RNA-positive patients exhibited 
decreased cell surface NCR NKp30 and NKp46 expression (21 0). Mechanistic 
studies are also inconclusive; some have shown that cross-l inking NK CD81 
receptors with recombinant HCV E2 protein or immobilized HCV particles directly 
inhibits NK cytotoxicity and cytokine production (211 , 212) , while others reported 
that NK cell functions remained intact when exposed to infectious HCVcc 
particles (213). In the absence of an immunocompetent small animal model of 
HCV infection, in vitro methods of investigating how NK cells behave in the 
context of HCV infection are required . As most previous systems used peripheral 
blood NK cells stimulated in vitro with recombinant IL-2 (rll -2), rll-12 or IFN-a 
combined with extended co-culture with HCV-infected cells , the in vivo relevance 
of the reported effects is uncertain (210-212, 214, 215) . 
Certain inhibitory receptor variants and corresponding ligands may provide 
protective effects against HCV, resulting in spontaneous clearance of HCV 
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infections. In order to maintain the functional recognition of rapidly evolving 
antigens in complex with MHC-1 , the NK cell KIR receptor genes must also evolve 
under pathogen-mediated pressure (216, 217) . KIR genotyping of individuals 
exposed to HCV illustrated that if a person expressed genes encoding both NK 
cell receptor KIR2DL3 and its cognate HLA C group 1 (HLA-C1) ligand, they were 
more likely to spontaneously resolve infection or make a SVR when treated (19, 
20). Interaction of KIR2DL3 and HLA-C1 results in a weaker inhibitory signal 
than other KIR :Iigand interactions allowing a greater functional response from NK 
cells (21, 22). KIR3DL 1 may also be involved in the regulation of chronic HCV 
infection, as expression of this NK cell receptor decreases in HCV-infected 
individuals (18). 
Both NK cell receptor or ligand expression can impact NK cell 
functions. Golden-Mason et a/. demonstrated that circulating levels of the Gal-9 
ligand for NK TIM-3 receptors are significantly increased in HCV-positive 
individuals compared to uninfected controls (218). As this interaction mediates 
an inhibitory response , this is one way in which HCV can establish and maintain 
chronic infection. Although there have been many studies examining the 
suppressive effect TIM-3 has in the context of effector T cell functions and HCV 
(219, 220) , the impact TIM-3 has on NK cells with respect to HCV infection has 
not been illustrated . 
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Natural killer cells have an important role in host responses to HCV 
infection, yet impaired NK cell activity is thought to contribute to the progression 
of chronic infection. The direct and indirect effects of HCV on NK cell activity is 
not well understood, therefore, we have investigated this utilizing an in vitro 
experimental system. In the absence of a suitable animal model, the HCV cell 
culture system allows in vitro analysis of the effect HCV has on innate immunity, 
in particular NK cells . Adaptation of the HCV cell culture system to a microtitre 
format enables in vitro study of the immediate effects HCV-infected human 
hepatoma (Huh-7.5) cells have on freshly isolated NK cells. We used this 
platform to explore how HCV-infected cells affect unstimulated ex vivo NK cells in 
short-term assays. Through the assessment of NK cell capability to lyse labeled 
target cells in the presence and absence of HCV-infected Huh-7.5 cells or titred 
HCVcc particles . Once we developed this in vitro system, we were then able to 
disturb potential molecular interactions between NK cells and HCV-infected Huh-
7.5 cells to gain mechanistic insights on the impact HCV-infected cells have on 
NK cells. 
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2 Materials and Methods 
2.1 Tissue Culture and Cell Line Maintenance 
Human hepatoma Huh-7.5 cells (a kind gift from Charles Rice, Rockefeller 
University) were maintained in complete Dulbecco's modified Eagle's medium 
(DMEM) consisting of 10% fetal calf serum (FCS) and 1% penicillin/streptomycin 
(P/S; all from Invitrogen). At confluency, Huh-7.5 cells were treated 6 minutes 
with 0.25% trypsin (Invitrogen) and removed from the plate, pelleted by 
centrifugation for 5 minutes at 290g, resuspended in 10 ml of complete DMEM, 
and either counted and plated for experiments, or re-seeded for maintenance. 
Human erythromyeloblastoid leukemia K562 cell line (American Type 
Culture Collection [ATCC]® #CCL 243™), C1 R-827 , an Epstein-Barr virus-
transformed human B lymphoblastoid cell line (BLCL) transfected with HLA-827 
(a kind gift from Kelly McDonald, University of Toronto) , and murine B lymphocyte 
hybridoma LS102.9 cell line (ATCC® #HB-97™) were propagated in lymphocyte 
medium consisting of Roswell Park Memorial Institute (RPMI)-1640 medium 
supplemented with 10% FCS, 200 IU/ml P/S, 1% 1 M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 1% L-glutamine (all from Invitrogen) and 
5.5 x 1 o-5 M 2-mercaptoethanol (Sigma-Aldrich). All cells were cultured at 3r C 
with 5% C02. 
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2.2 Transformation of Competent Bacteria 
JFHh (amino acid mutations N417S, N765D, 01 012R, where amino acid 
numbering begins with the first residue in the complete polyprotein) was obtained 
from S.U. Emerson and R.H. Purcell (Laboratory of Infectious Diseases, National 
Institute of Allergy and Infectious Diseases, National Institute of Health, 
Bethesda, USA) (221). Pre-existing JFHh or JFH1o1 (amino acid mutations 
N765D, 01 012R) DNA clones were diluted to a concentration of -0.1 1-Jg/1-JI in 
deionised molecular biology grade water (dH 20). Aliquots of 40 1-JI MAX 
Efficiency® DH5a™ Competent Escherichia coli (E.co!J) cells (Invitrogen) were 
thawed on ice. An amount of 1 1-JI diluted DNA was added to a 40 1-JI aliquot of 
E. coli cells and incubated on ice for 30 minutes. For transformation , competent 
E. coli cells were heat shocked for 45 seconds at 42°C, then incubated on ice for 
2 minutes, after which time 150 1-JI of super optimal broth with catabolite 
repression (S.O.C. ; Invitrogen) was added to each aliquot and incubated for 
1 hour at 3TC with constant shaking at 225 rpm to allow expression of the 
ampicillin (amp) gene. After 1 hour incubation , 800 1-JI of S.O.C. was added and 
20 IJI and 100 IJI plated on lysogeny broth (LB) agar plates inoculated with amp 
(Section 2.4) and incubated at 3TC overnight (16 hours). 
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2.3 Large-Scale DNA Generation (Maxiprep) 
To generate viral plasmid DNA, a transformed E. coli bacteria colony 
(Section 2.2) was used to inoculate 150 ml of LB broth contain ing 0.1 % amp 
(Section 2.5) at 3rc with shaking at 225 rpm overnight. Inoculated LB broth was 
transferred to a 250 ml nalgene centrifuge tube and pelleted by centrifugation in a 
Sorvall RC 6 Plus Thermo Scientific centrifuge at 6,000g for 15 minutes at 4°C. 
The DNA pellet was purified using the QIAGEN Plasmid Maxi Kit. To lyse 
bacteria , the pellet was resuspended in 10 ml buffer P1 (resuspension buffer) 
followed by adding 10 ml of buffer P2 (lysis buffer) . Contents were vigorously 
mixed by inversion and incubated for 5 minutes at room temperature. To 
precipitate DNA, 10 ml chilled buffer P3 was added and contents were 
immediately mixed by inversion and incubated for 20 minutes on ice. Cellular 
debris was pelleted by centrifugation at 20,000g for 10 minutes at 4 oc and 
supernatant was gravity filtered through an equilibrated QIAGEN-tip 500 column 
then washed two times each with 25 ml of buffer QC (wash buffer) by gravity 
flow. Purified DNA was eluted with 15 ml of buffer QF (elution buffer), eluate was 
collected in a 50 ml nalgene centrifuge tube (Thermo Scientific) , precipitated with 
1 0.5 ml isopropanol, mixed by inversion , and immediately pelleted by 
centrifugation at 15,000g for 15 minutes at 4 oc . Supernatant was carefully 
decanted and the DNA pellet washed with 5 ml of 70% ethanol and centrifuged at 
15,000g for 10 minutes, after which time the supernatant was carefu lly decanted . 
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The DNA pellet was left to air-dry -5 minutes, then redissolved in 300 ~I dH20. 
DNA concentrations were determined using a Beckman Coulter DU 530 UVNis 
Spectrophotometer. 
2.4 LB Broth and Agar 
Bacteria growth medium was made by dissolving 20 g of LB broth (1 0 g 
tryptone, 5 g NaCI, 5 g yeast extract; Fisher Scientific) into 1 litre dH20 and 
sterilizing in an autoclave. Before use, LB broth was treated with 100 ~g amp/ml 
broth . LB agar plates were made by dissolving 40 g of LB agar (1 0 g tryptone, 
10 g NaCI, 5 g yeast extract, 15 g agar; Fisher Scientific) into 1 litre dH20 and 
sterilizing by autoclave. While warm, LB agar was treated with 100 ~g amp/ml 
agar and poured into 10 em dishes to cool. LB agar/amp plates were stored at 
4°C unti l use. 
2.5 DNA Linearization 
Purified JFHh or JFH1 0 1 plasmid DNA was linearized with restriction 
enzyme Xbal (Invitrogen) for RNA synthesis and transfection. 25 ~g of plasmid 
DNA was digested with 75 units (5 ~I) Xbal , 5 ~I 10x buffer M (100 mM Tris-HCI 
at pH=7.5, 100 mM MgCI2, 10 mM dithiothreitol , 500 mM NaCI) , 5 ~I 0.1% bovine 
serum albumin (BSA; all from Invitrogen) in a total reaction volume of 50 ~ I for 
2 hours at 3r C. Linearized DNA was extracted using phenol/chloroform 
(Section 2.6). 
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2.6 Phenol/Chloroform Extraction 
Linearized DNA (Section 2.5) was treated with phenol/chloroform/isoamyl 
alcohol, 25:24:1 v/v, (Invitrogen) for purification at a 1:1 ratio. To the linearized 
DNA, 50 IJI of dH20 was added to make the reaction mixture up to 100 IJI , then 
100 IJI of phenol/chloroform/isoamyl alcohol was combined , vortexed and then 
centrifuged at 14,000g for 3 minutes. 100 1-11 of the upper aqueous layer 
(containing nucleic acids) was transferred to a clean microcentrifuge tube and 
precipitated with 100% ethanol (Section 2.7). 
2.7 Ethanol Precipitation 
Linearized DNA extracted by phenol/chloroform/isoamyl alcohol was 
precipitated with NaCI (Sigma-Aldrich) and 100% ethanol. A 5 M solution of NaCI 
was added to the aqueous layer in Section 2.6 to a final concentration of 250 IJM 
(3 IJI), followed by addition of 2 .5 volumes of 100% ethanol (230 IJI) and stored at 
-20°C for at least 30 minutes. Following a 10 minute centrifugation at 14,000g, 
the supernatant was decanted and the pellet was washed in 300 IJI of 70% 
ethanol then centrifuged for an additional 5 minutes at 14,000g. Supernatant was 
decanted and the extracted , linearized DNA was resuspended in 30 IJI dH20. 
Linearized DNA concentrations were determined as in Section 2.3. 
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2.8 In Vitro RNA Transcription 
Linearized viral DNA was in vitro transcribed into RNA using the T7 
RiboMAX Express large-scale RNA production system (Promega). For every 
1 IJg of linearized DNA, 5 IJI RiboMAX™ Express T7 2x Buffer, 2 IJI T7 Express 
enzyme mix (T7 RNA polymerase, recombinant RNasin® ribonuclease inhibitor, 
recombinant inorganic pyrophosphatase) and nuclease-free dH20 were combined 
in a 10 IJI reaction mixture and incubated at 3rC for 30 minutes as per the 
manufacturer's specifications. The Express T7 2x buffer contains a precipitate 
that must be dissolved by warming the buffer at 3rC and mixing well prior to 
use. 
2.9 In Vitro RNA Transfection 
To generate infectious virus stock, Huh-7 .5 cells were transfected with 
linearized genomic RNA derived from JFHh or JFH1 01 plasmid DNA (Sections 
2.5-2.8). Huh-7.5 cells (1.25 x 1 06 ) were seeded in 10 em tissue culture-treated 
dishes, and then 24 hours later transfected with JFH1r or JFH1 o1 RNA using 
DMRIE-C transfection reagent (Invitrogen) (82) . 4 IJI of transcribed RNA was 
combined with 500 IJI serum-free (SF) DMEM and 50 IJI DMRIE-C, and then 
added to cells plated with 2 ml SF DMEM. After 4 hours incubation, SF DMEM 
was replaced with fresh complete DMEM. Seventy-two hours post-infection, 
supernatants were collected and filtered using MillexHV 45 1-1m filters (Millipore). 
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2.10 Infectious HCV Titre Determination 
To determine the infectious virus titre of HCVcc in supernatant, 5 x 104 
Huh-7.5 cells were seeded/well in 8-well chamber slides (Lab-Tek). Twenty-four 
hours later, infectious supernatant was 1 0-fold serially diluted in complete DMEM 
and 100 IJI of each dilution added to Huh-7.5 cells in 8-well chamber slides 
(performed in triplicate) . Infectious supernatant was removed after a 4 hour 
incubation and replaced with complete DMEM. Seventy-two hours post-infection, 
Huh-7.5 cells were fixed in reagent grade acetone and anti-HCV core protein 
expression was assessed (Section 2.12.1) to determine focus forming units per 
ml (ffu/ml) of supernatant by indirect immunofluorescence. 
2.11 Generation of Infectious HCVcc Stock 
To generate infectious HCVcc stock, 1.25 x 106 Huh-7.5 cells seeded in 
1 0 em culture-treated dishes were subsequently infected for 4 hours with titred 
HCVcc supernatant (Section 2.9, 2.1 0) at a multiplicity of infection (MOl) of 0.5. 
The infectious supernatant was removed and replaced with 6 ml of complete 
DMEM. Seventy-two hours post-infection, supernatants were removed , fi ltered 
and titred as in Sections 2.1 0, 2.12.1. Transfection supernatants were passaged 
twice to dilute input RNA from transfection. The final infectious virus titre , in 
ffu/ml of HCVcc supernatant, was used for all subsequent assays. 
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2.12 Indirect Immunofluorescence 
2.12.1 Determination of Infectious HCV Titre 
Huh-7.5 cells, seeded and infected in 8-well chamber slides (Section 
2.1 0) , were washed with phosphate-buffered saline (PBS) and fixed for 2 minutes 
with reagent grade acetone. Slides were incubated with murine monoclonal anti-
HCV core (B2; Anogen) at a final concentration of 0.2 ~gfi..JI diluted in 5% 
BSA/PBS (Sigma-Aldrich) for 20 minutes at room temperature. Chamber slides 
were washed once for 10 minutes with PBS, then incubated with a 1:1000 dilution 
of secondary antibody goat anti-murine lgG conjugated with AlexaFiuor®488 
(Invitrogen) in PBS for 20 minutes at room temperature. Cells washed with PBS 
were then fixed and mounted using Vectasheild with 4' ,6-diamidino-2-
phenylindole (DAPI) and mounting medium (Vector Labs) (221 ). Images were 
visualized at x1 0, x20 or x40 magnification on a Zeiss Axio lmager.M2 IF 
microscope. 
2.12.2 Intra- and Extracellular HCV E2 
For HCV E2 protein visualization , 105 Huh-7.5 cells were plated in 2-well 
chamber slides (Lab-Tek® II Chamber Slide ™ Fisher Scientific) . Twenty-four 
hours later, cells were infected with JFH1 0 1 HCVcc at a MOl of 1.25. Seventy-
two hours post-infection , cells were washed 3 times with PBS and both unfixed 
cells or cells f ixed for 20 minutes with 2% formaldehyde (FA, paraformaldehyde 
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in PBS; Sigma-Aldrich) were stained with a final concentration of 0.2 IJg/IJI of anti-
HCV E2 (AP33; Genentech) or lgG1 isotype control (eBioscience) diluted in 5% 
BSA/PBS for 20 minutes. Cells were washed with PBS, then incubated with a 
1:1 000 dilution of secondary antibody goat anti-murine lgG conjugated with 
AlexaFiuor®488 in PBS for 20 minutes. Cells were washed with PBS , then fixed 
and mounted using DAPI with mounting medium. For a positive control , cells 
fixed with 2% FA were permeabilized with 0.1% Tween® 20 (Sigma-Aldrich) in 
5% BSA/PBS for 10 minutes, then stained and washed as above with the 
exception that diluents and wash consisted of 0.01 % Tween® 20 in 0.5% 
BSA/PBS. Images were visualized at x1 0 or x40 magnification on a Zeiss Axio 
lmager.M2 IF microscope. 
2.13 Isolation of PBMCs and NK Cell Purification 
PBMCs were freshly isolated from whole blood of consenting healthy 
donors by density gradient centrifugation using Ficoii-Paque lymphocyte isolation 
solution (VWR) on the day of the assay and suspended at 5 x 1 06 cells/ml in 
lymphocyte medium. PBMCs were used in all assays unless otherwise stated. 
For assays using purified NK cells , cells were enriched from isolated PBMCs by 
negative selection using EasySep ™ Human NK Cell Enrichment Cocktail 
(STEMCELL Technologies) , as per the manufacturer's specifications, and re-
suspended at 106 cells/ml in lymphocyte medium (Section 2.1 ). This study 
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received ethical approval for the collection of human blood samples from the 
Health Research Ethics Authority of Newfoundland and Labrador, Canada. 
2.14 51 Chromium Release Assays 
2.14.1 Natural Cytotoxicity and ADCC 51 Chromium Release 
Five hour 51 Chromium release assays were used to assess the effect of 
HCV-infected Huh-7.5 cells on NK cell cytotoxicity. Huh-7.5 cells (5 x 103) were 
seeded/well in a volume of 100 ~I in 96-well round bottom tissue culture-treated 
plates (Falcon) then 24 hours later, infected at various MOis with titred infectious 
JFHh HCVcc stocks (Sections 2.11 and 2.12.1). Seventy-two hours later, K562 
or C1 R-827 cells were labeled for 90 minutes with 100 IJCi Na251Cr04 (51 Cr; MP 
Biomedicals) then washed 4 times with PBS containing 1% FCS. C1 R-827 cells 
were subsequently incubated for 30 minutes with 2 ml of W6/32 (mouse 
monoclonal lgG2a anti-human MHC-1) supernatant (ATCC® #HB-95™) to 
sensitize cells to ADCC (222) . PBMC isolated from healthy donors served as 
effector cells. Immediately prior to the addition of effector and target cells , Huh-
7.5 supernatant was removed and replaced with fresh complete DMEM. Huh-7.5 
cells were incubated for 5 hours with freshly isolated PBMC and 5x1 03 51 Cr-
labeled K562 or C 1 R-827 target cells at various effector to target (E:T) ratios in a 
final reaction volume of 295 IJI/well. Supernatant (125 IJI) was then removed from 
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each well , transferred to glass Kimble tubes (Fisher) and 51 Cr release measured 
on a Wallac 1480 Wizard gamma counter. Percent specific lysis was calculated 
by (experimental 51 Cr release - spontaneous 51 Cr release) I (maximum 51Cr 
release - spontaneous 51 Cr release) X 100. Replicates were performed as 
indicated in each experiment. Spontaneous 51Cr release was less than 10% or 
15% of maximum 51 Cr release in all assays using K562 and C 1 R-B27 as target 
cells , respectively. Immediately post-assay, the microtitre plate was washed 4 
times with PBS to remove non-adherent cells and radioactivity. The remaining 
adherent Huh-7.5 cells were fixed in acetone as described , and a cell-based 
enzyme-linked immunosorbent assay (CELISA) performed as in Section 2.15. 
2.14.2 Cell-Free 51 Chromium Release 
To determine whether cell-free virus affected NK cell functions, freshly 
isolated PBMC and 51 Cr-labeled K562 target cells were incubated with or without 
varying amounts of titred infectious JFHh HCVcc stock. An amount of -50,000 
ffu/well were incubated with PBMC and 51Cr-labeled K562 target cells for 5 hours, 
after which time 51Cr release was measured as in Section 2.14.1. 
2.14.3 Inert Huh-7.5 51Chromium Release 
For fixed Huh-7.5 cell 51 Cr release assays, Huh-7.5 cells were infected as 
in Section 2.14.1. On the day of the assay, cells were washed with PBS, fixed for 
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20 minutes in 2% FA, washed 4 times with PBS, then effector and 51 Cr-labeled 
K562 target cells incubated for 5 hours and 51 Cr release measured . 
2.14.4 Z-VAD-FMK-Treated Huh-7.5 51 Chromium Release 
To block apoptosis, cells were treated with the pan caspase inhibitor 
carbobenzoxy-valyl-a Ia nyl-aspa rtyl-[0-methyl]-fl uoromethylketo ne (Z-VAD-FM K; 
Tocris Bioscience) . Huh-7.5 cells were seeded and infected with JFHh HCVcc 
as indicated and treated with 20 IJM Z-VAD-FMK 24 hours prior to cytotoxicity 
assays (223) . 
2.14.5 LS102.9 51 Chromium Release 
To determine whether apoptotic cells affected NK cell cytotoxicity, LS102.9 
cells were untreated or pre-treated for 3 hours with 1 IJg hamster anti-murine Fas 
antibody per 106 cells (Jo-2; BD Pharmingen) to induce apoptosis (224). 
Untreated and anti-Fas-treated LS1 02.9 cells were incubated in a 5 hour 51 Cr 
release assay with PBMC and 51Cr-labeled K562 cells at an E:T of 60:1. Viability 
of untreated and anti-Fas-treated LS102.9 cells was measured at the completion 
of the assay (8 hours post-treatment) by trypan blue staining (Section 2.20). 
2.14.6 Trans-Well Co-Culture Assay 
To determine whether HCV-infected cells or cell-free HCV affected NK cell 
cytotoxicity , Huh-7.5 cells were seeded at 7.5 x 103 cells/well and infected with 
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JFH h HCVcc (Section 2.14.1) in a HTS Transwell®-96 well receiver microplate 
(Corning). Seventy-two hours post-infection , 51 Cr-labeled K562 target cells and 
freshly isolated PBMCs were incubated for 5 hours in 3.0 J.Jm membrane inserts 
placed in receiver plates with uninfected or HCV-infected Huh-7.5 cells and 51Cr 
release measured. 
2.15 Cell-Based Enzyme-Linked lmmunosorbent Assay (CELISA) 
To measure relative HCV protein levels, CELISA assays were performed. 
51 Cr release assay plates, containing fixed HCV-infected Huh-7.5 cells (Section 
2.14.1 ), were washed 3 times with PBS containing 1% Tween® 20 (wash buffer; 
Sigma-Aldrich). Human plasma from an HCV-infected subject (Donor 153) was 
diluted 1:200 in wash buffer containing 1% FCS (diluent) and 100 IJI of diluted 
serum added to each well of the 96-well plate for 90 minutes at room 
temperature. Following 4 washes with wash buffer, 100 !JI of 1:5,000 diluted 
alkaline phosphatase (AP)-conjugated goat anti-human lgG (Jackson 
Laboratories) was added to each well for 60 minutes at room temperature. After 
4 washes with wash buffer, 100 !JI of substrate (1 p-nitrophenol tablet [Sigma-
Aldrich] dissolved in 12 ml of AP substrate buffer [1 0% diethanolamine {BDH}, 
0.02% sodium azide and 0.01% magnesium chloride {both from Sigma-Aldrich} 
pH=9.8]) was incubated in each well for 30 minutes at room temperature in the 
dark. Absorbance was read at 405 nm on a Synergy™ HT BioTek microplate 
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reader. Measured absorbance at MOl 0 was considered to be background and 
subtracted from all values. 
2.16 Huh-7.5 Cell Viability Assay 
To assess HCV cytopathic effects, Huh-7.5 cells were seeded in 96-well 
plates and infected with titred JFHh HCVcc (Sections 2.11 and 2.12.1) at various 
MOis as in Section 2.14.1. Seventy-two hours post-infection, supernatant was 
removed and cells were incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium-bromide (MTT; Sigma-Aldrich) diluted 1:10 in complete 
DMEM for 4 hours. The MTT medium was then removed , and cells were 
dissolved in dimethyl sulfoxide (DMSO). Absorbance was immediately read at 
540 nm on a Synergy™ HT BioTek microplate reader. 
2.17 Flow Cytometry 
Huh-7.5 cells were seeded at 6.5 x 104 cells/well in a 12-well plate and 
infected with JFHh HCVcc (Sections 2.11 and 2.12.1) at a MOl of 3.2 or 4.8. 
Seventy-two hours later, Huh-7.5 cells were stained for HLA-E expression (1 
IJg/1 06 cells , clone 3012; Biolegend) and measured as below, or were incubated 
with freshly isolated PBMCs with or without K562 cells at an E:T of 5:1 for 1 hour 
at 3rC, after which 10 ug/ml Brefeldin A (Sigma-Aldrich) was added for an 
additional 4 hours. After a 5 hour incubation , PBMCs were removed , washed 
with flow cytometry buffer (0.2% sodium azide, 0.5% FCS, 5 mM EDTA in PBS) , 
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and incubated for 20 minutes with 0.4 1-Jg/1 06 cells peridinyll-chlorophyll protein 
(PerCP)-conjugated murine anti-human CD3 (Biolegend) , 1 1-Jg/1 06 cells 
fluorescein isothiocyanate (FITC)-conjugated murine anti-human CD56 
(eBioscience) , 1 1-Jg/1 06 cells of phycoerythrin (PE)-conjugated murine anti-
human CD1 07a (Biolegend) , anti-NKp30-APC, anti-NKp46-PE, or anti-NKG2D-
PE (Biolegend) for NK cell surface markers. Cells were fixed and permeabilized 
with lntraStain kits (Dako) then incubated 20 minutes with 0.1 1-Jg/1 06 cells 
allophycocyanin (APC)-conjugated murine anti-human IFN-y (eBioscience), or 
1 1-Jg/1 06 cells APC-conjugated anti-human TN F-a (MAb11 ; Biolegend) or 
1 1-Jg/1 06 cells PE-conjugated anti-human IL-4 (80 Pharmingen ™) or 1 1-Jg/1 06 
cells PE-conjugated anti-human IL-10 (80 Pharmingen ™), washed then fixed 
with 1% FA. 
For fusion protein experiments, uninfected or HCV-infected Huh-7.5 cells 
were incubated 30 minutes at 4°C with NKp30-lgG1 Fey chimera or control 
KIR3DS1-IgG1 Fey chimera (1 1-Jg/1 06 cells) , and stained with APC-conjugated 
AffiniPure goat anti-human lgG1 Fey (Jackson Laboratories) . Fresh PBMCs were 
stained with 1 1-Jg primary antibody LEAF™ murine anti-human TIM-3 (F38-2E2; 
Biolegend), washed then incubated with 0.02 1-Jg secondary antibody FITC-
conjugated goat anti-murine lgG Fe (Jackson Laboratories) for analysis of TIM-3 
expression. Cells were analyzed on a Becton Dickinson FACS Calibur flow 
cytometer. 
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2.18 Propidium Iodide Staining to Detect Huh-7.5 Cell Apoptosis 
The efficacy of caspase inhibitor Z-VAD-FMK to prevent apoptosis of Huh-
7.5 cells was measured by propidium iodide (PI) binding and subsequent labeling 
of cellular DNA content, and assessed by flow cytometry. Huh-7.5 cells were 
seeded at 6.5 x 106 cells/well in a 12-well plate and uninfected or Huh-7.5 cells 
infected with JFHh HCV at MOl 4.8 were treated for 24 hours with or without 
20 1-1M Z-VAD-FMK in DMEM. Twenty-four hours post-treatment, Huh-7.5 cells 
were removed from the 12-well plates using a cell scraper and PBS, transferred 
to a 15 ml tube and pelleted at 200g for 5 minutes. Supernatant was decanted 
and the pellet re-suspended in 500 1-11 of PBS. Cells were fixed by adding 4.5 ml 
of ice-cold 70% ethanol to the re-suspended pellet and stored at -20°C for at 
least 24 hours (up to several weeks) . 
Cells were centrifuged at 400g for 5 minutes, the ethanol was decanted , 
and cells were washed with 5 ml of PBS and pelleted for 5 minutes at 400g. 
Cells were then resuspended in 500 1-JI of PBS and 500 1-JI of DNA extraction 
buffer (consisting of 192 ml of 0.2 M Na2HP04 [Sigma-Aldrich] and 8 ml of 0.1% 
Triton X-1 00 [Sigma-Aldrich] at pH=7.8). After 5 minutes of incubation at room 
temperature, cells were pelleted at 400g for 5 minutes and the supernatant 
decanted. Cells were resuspended in 1 ml of freshly-prepared DNA staining 
solution (200 1-Jg of PI [Sigma-Aldrich] dissolved in 10 ml of PBS and 2 mg of 
DNase-free RNase [Sigma-Aldrich]) , and incubated in the dark at room 
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temperature for at least 30 minutes. Cells were analyzed as described in Section 
2.17 by flow cytometry using a 488 nm laser for excitation (225). 
2.19 Antibody-Mediated Receptor/Ligand-Masking 
To block receptor:ligand interactions, freshly isolated PBMCs were pre-
treated for 30 minutes at 4 ac with either 1 IJg/1 06 cells of isotype control (IC; Ag8 , 
a kind gift from Chris Ford, Memorial University of Newfoundland), murine anti-
human CD81 (JS-81 ; BD Biosciences) or murine anti-human LEAF™ TIM-3 
monoclonal antibodies. PBMCs were washed once, resuspended in lymphocyte 
medium (Section 2.1) then incubated in a 51Cr release assay as in Section 2.14.1 
with uninfected or HCV-infected Huh-7.5 (PBMCs pre-treated with anti-TIM-3 or 
anti-CD81) or LS102.9 (PBMCs pre-treated with anti-TIM-3) cells . Alternatively, 
96 hours post-infection with JFH1 01 HCVcc at a MOl of 1.3 (Section 2.11 ), Huh-
7.5 cells were pre-incubated for 30 minutes with either 1 IJg/well anti-human HCV 
E2 or IC antibodies diluted in complete DMEM, and then incubated with target 
and effector cells in a 51Cr release assay as in Section 2.14.1. 
2.20 LS1 02.9 Cell Viability Assay 
Trypan blue (0.4% trypan blue in 0.85% NaCI [both Sigma-Aldrich]) 
staining was used to asses LS1 02.9 cell viability. Untreated and anti-Fas-treated 
LS102.9 cells were diluted 1:1 in trypan blue and a live to dead cell ratio was 
determined by counting cells using a hemocytometer. 
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2.21 Statistical Analysis 
Statistical analysis was performed using Graph Pad Prism software. Effects 
were tested using a two-tailed Student's paired t test (Gaussian distribution) or a 
Mann-Whitney U test (non-parametric distribution) and are indicated . A p ::; 0.05 
was considered to be statistically significant. 
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3 Modulation of Natural Killer Cell Functions by HCV 
3.1 Rationale 
HCV successfully evades the immune system and establishes chronic 
infection in approximately 80% of cases. As successful immune evasion is key 
for the persistence of any pathogen , one strategy that HCV employs to establish 
persistence may involve modulating NK cell functions. Therefore, we developed 
a short term assay to assess immediate effects of HCV-infected cells on ex vivo 
NK cell cytotoxicity and cytokine production. 
3.2 Development of a Novel Assay Platform to Detect the Effects of 
HCV on NK Cells 
To study the effects HCV-infected Huh-7.5 cells have on NK cell functions, 
we developed a microtitre assay by infecting Huh-7.5 cells in 96-well microtitre 
plates with JFHh (221) or JFH1 01 HCVcc (Figure 3.1). Virus stocks were 
generated from passaged transfection supernatant and titred to determine the 
levels of infectious virus titres. Viral titres used were greater than 4 x 105 ffu/ml. 
Huh-7.5 cells were infected for 72 hours at a MOl of 0, 0.2, 0.4, 0.8 , 1.6, 3.2, 4.8 
then a CELISA was used to assess the extent of infection. As MOl increased, we 
observed a 6-fold increase in relative HCV protein levels compared to MOl 0.2, 
detectable by antibodies present in HCV positive patient plasma (Figure 3.2 A). 
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MTT assays were performed in parallel with CELISA to assess Huh-7.5 cell 
viability following infection. As the extent of HCV infection increased , cell viability 
decreased, falling as much as 40% at high MOis (Figure 3.2 B). The extent of 
HCV infection in Huh-7.5 cells was also visualized by IF microscopy with greater 
degrees of infection noted at higher MOis compared to the lower MOis (Figure 
3.2 C). As 80-90% of the Huh-7.5 cells stained positive for HCV core proteins, a 
MOl of 3.2 or 4.8 was chosen for subsequent experiments to optimize virus 
infection levels in this system. 
3.3 HCV-Infected Huh-7.5 Cells Reduce NK Cell Cytotoxicity 
NK cell functions in the presence of HCV-infected Huh-7.5 cells were 
assessed using a classic 5 hour 51 Cr release assay. Target cells and freshly 
isolated PBMCs from 12 consenting healthy donors were incubated with 
uninfected or JFHh HCV-infected Huh-7.5 cells in microtitre format and NK cell 
cytotoxicity evaluated. The presence of HCV-infected Huh-7.5 cells reduced NK 
cell cytotoxicity against K562 cells by a mean of 23 ± 2.2% (standard error of the 
mean [SEM] ; p < 0.0001 , Student's paired t test; n = 12) (Figure 3.3 A) . To 
determine whether alternate mechanisms of NK cell cytotoxicity were affected by 
HCV-infected Huh-7.5 cells, we used anti-HLA class 1-coated BLCL as targets in 
an ADCC 51 Cr release assay. The presence of HCV-infected Huh-7.5 cells 
reduced NK ADCC by a mean of 18 ± 6.0% (SEM; p = 0.001 , Student's paired t 
test; n = 6) compared with NK ADCC in the presence of uninfected Huh-7.5 cells 
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(Figure 3.3 B) . Although different donors had varying levels of NK cytotoxicity, 
the percent decline in cytotoxicity was consistently between 20-27%, and all 
healthy donors displayed a significant reduction of NK cell cytotoxicity in the 
presence of HCV-infected cells. To determine if this was a direct effect on NK 
cells, or mediated through another PBMC subset, we purified NK cells from fresh 
PBMCs. Purified NK cells (85-95% purity, data not shown) also exhibited 15 ± 
2.4% (SEM; p = 0.0001 , Student's paired t test; n = 6) lesser cytotoxicity, on 
average, in the presence of HCV-infected Huh-7.5 cells compared to uninfected 
Huh-7.5 cells (Figure 3.3 C) . Thus, HCV-infected cells have a negative effect on 
both general NK cell cytotoxicy as well as ADCC functions in this short-term 
experiment. 
3.4 HCV-Infected Huh-7.5 Cells Reduce NK Cell Degranulation. 
IFN-y and TNF-a Production 
We next investigated whether HCV-infected cells perturbed NK cell 
degranulation and cytokine production over a 5 hour incubation period . Flow 
cytometry of the CD56+Co3- PBMC population revealed reduced NK cell 
degranulation by a mean of 33% (p = 0.0313, one-tailed Wilcoxon signed rank 
test; n = 5) , as measured by CD1 07a expression , in the presence of HCV-
infected Huh-7.5 cells compared with uninfected Huh-7.5 cells (Figure 3.4 A) . 
This corroborated the effects observed on NK cell cytotoxicity in the 5 hour K562 
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51Cr release assay. Analysis of permeabilized CD56+Co3- PBMCs also indicated 
that NK cell IFN-y and TNF-a expression were reduced in the presence of HCV-
infected Huh-7.5 cells by a mean of 26% and 18%, respectively (p = 0.0156, one-
tailed Wilcoxon signed rank test; n = 6; Figure 3.4 A,B). We observed no 
difference in NK IL-4 or IL-10 release in the presence of uninfected versus HCV-
infected Huh-7.5 cells (Figure 3.4 C) . These data demonstrate a generalized 
effect that HCV-infected Huh-7.5 cells have on NK cell activation , affecting both 
cytotoxicity and cytokine production. 
3.5 HCV-Infected Cells Inhibit NK Cell Functions by Direct Contact 
Since infectious virus particles are released from HCV-infected Huh-7.5 
cells , we next determined whether cell-free HCV particles, soluble factors 
released from HCV-infected cells , or the HCV-infected Huh-7.5 cells themselves 
mediated inhibited NK cell functions. PBMCs were incubated in a 5 hour 51 Cr 
release assay with titred infectious cell-free HCVcc, or complete DMEM as a 
control. Cell-free virus had no significant effect on NK cell cytotoxicity, as 
assessed by 51 Cr-labeled K562 lysis (Figure 3.5 A). 
To evaluate whether either cytokines or other soluble factors were down-
regulating NK cell functions, we performed a 5 hour trans-well assay in which 
both PBMCs and target cells were sequestered from direct contact with 
uninfected or HCV-infected Huh-7.5 cells. While a 7-27% (p = 0.0034, Student's 
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paired t test; n = 6) decline in NK cell cytotoxicity was noted when PBMCs were 
in direct contact with HCV-infected Huh-7.5 cells, we only observed a 0-11% (n = 
6) decline in NK cell cytotoxicity when PBMCs were segregated from HCV-
infected Huh-7.5 cells (Figure 3.5 B). These results suggest that neither cell-free 
virus nor soluble factors released from HCV-infected Huh-7.5 cells inhibit NK 
cytotoxicity. Thus, direct cell-cell contact between NK cells and HCV-infected 
Huh-7.5 cells is necessary to inhibit NK cell functions . Inhibition of NK cell 
functions relies on an active interaction with HCV-infected Huh-7.5 cells as FA-
fixed Huh-7.5 cells did not support a decline in NK cell cytotoxicity (Figure 3.5 C). 
Although fixation with FA generally preserves the cellular structure close to its 
native state (226), it is possible that the absence of NK cell inhibition in the 
context of FA-fixed HCV-infected Huh-7.5 cells may be caused by the destruction 
of important epitopes during this fixation process. 
We also noted that NK cell inhibition was directly related to HCV infection 
levels of Huh-7.5 cells. At a MOl of 4.8 and the greatest relative levels of HCV 
proteins, we observed the most inhibition of NK cell cytotoxicity (Figure 3.6) . 
Therefore, not only is NK cell inhibition dependent on cell-cell contact with HCV-
infected Huh-7.5 cells, but our data suggest that this effect is directly related to 
the extent of HCV infection. 
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3.6 Blocking HCV E2 Protein Has No Effect on NK Cells, Whereas 
Engagement of NK CD81 Abrogates Inhibition 
Previous studies indicated that HCV E2 protein binding to NK CD81 can 
affect NK cell function (211, 212). Although we could not detect cell surface HCV 
E2 expression on HCV-infected Huh-7.5 cells by IF microscopy (Figure 3.7 A) , 
we performed antibody-masking experiments to determine whether an E2:CD81 
interaction could down-regulate NK cell functions in our system. JFHh has a 
mutation at amino acid 417 in E2 (N-7S) that prevents anti-HCV E2 monoclonal 
antibody AP33 binding (227), therefore, this antibody could not be used in these 
experiments . JFH1 01 lacks the E2 adaptive mutation but invokes the same 
effects on NK cell cytotoxicity as JFH1 T (shown in Figure 3.7 B) . JFH1 01 HCV-
infected Huh-7.5 cells were pre-treated with an anti-HCV E2 monoclonal antibody 
(AP33), which binds E2 at amino acid residues 412-423 and blocks CD81 :E2 
interactions, then incubated with PBMCs in a 5 hour 51Cr release assay. Pre-
treating HCV-infected cells with anti-HCV E2 to block potential HCV E2:NK CD81 
interactions did not abrogate NK cell inhibition (Figure 3.7 B). Interestingly, pre-
treating fresh PBMCs with a soluble CD81 antibody prior to 51 Cr release assays 
with JFHh HCV-infected Huh-7.5 cells negated NK cell cytotoxic inhibition 
(Figure 3.7 C). The purpose of the experiments involving soluble anti-human 
CD81 antibody was to not cross-link this receptor on NK cells , but merely block 
interactions involving this receptor to ascertain whether it was involved in 
76 
inhibiting NK cell functions. Pre-treatment of PBMCs with soluble anti-CD81 
alone had no effect on NK cell cytotoxicity in control assays using 51 Cr-labeled 
K562 cells (Figure 3.7 D). These results imply that it is unlikely that HCV E2 is 
present on the surface of HCV-infected Huh-7.5 cells at levels sufficient to 
mediate the observed inhibition, and that the mechanism by which pre-treating 
PBMCs with soluble anti-CD81 abrogates HCV-infected Huh-7.5 cell inhibition of 
NK cell cytotoxicity is E2-independent. 
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3.7 Direct Interaction with HCV-Infected Cells Down-Regulate 
NKp30 Expression 
To address the mechanism by which HCV-infected Huh-7.5 cells inhibit 
NK cell functions, we examined surface expression of various NK cell receptors. 
Flow cytometric data showed that NKp46, CD16 and NKG2D expression levels 
remain unaltered over a 5 hour incubation of PBMCs with HCV-infected 
compared to uninfected Huh-7.5 cells (Figures 3.8 A-C). Previous studies 
indicated that cell surface HLA-E complexes can be stabilized by a peptide 
derived from HCV core protein and its expression up-regulated upon HCV 
infection (228) . However, we saw no increase of HLA-E expression on Huh-7.5 
cells following HCV infection (Figure 3.9). In contrast, we found that NCR NKp30 
expression was down-regulated by a mean of 18 ± 4.6% (SEM; p = 0.0030, 
Student's paired t test; n = 6) , assessed by mean fluorescence intensity (MFI) 
following 5 hour incubation with HCV-infected Huh-7.5 cells (Figure 3.10 A). As 
NKp30 exhibited selectively reduced expression, and direct cell-cell contact with 
HCV-infected cells was required to inhibit NK cell functions, we examined 
whether a putative NKp30 ligand was up-regulated on Huh-7.5 cells following 
HCV-infection . We observed a - 20% increase in surface binding of an NKp30-
lgG1 Fey fusion protein to HCV-infected Huh-7.5 cells (MOl 4.8) in comparison 
with uninfected Huh-7.5 cells (Figure 3.10 B). To account for potential non-
specific binding of NKp30-lgG1 Fey fusion proteins to the Huh-7.5 cell surface, we 
81 
compared binding of KIR3DS1-IgG1 Fey fusion proteins to uninfected and HCV-
infected Huh-7.5 cells. There was no increased binding of the KIR3DS1 -IgG1 Fey 
fusion protein to HCV-infected compared to uninfected Huh-7.5 cells (Figure 3.10 
C). However, there was a 2-fold (p = 0.0286, Mann-Whitney U test; n = 4) 
increase in NKp30-lgG1 Fey protein binding to HCV-infected over uninfected Huh-
7 .5 cells (Figure 3.10 C) . This suggests that HCV infection up-regulates an 
antagonistic ligand that binds the NKp30 receptor, which could impact NK cell 
cytotoxicity and cytokine production . 
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4 The Effect of Apoptotic Cells on NK Cell Functions 
4.1 Rationale 
Although data suggests that the decline in NK cell functions is likely 
directly related to HCV infection of Huh-7 .5 cells, it was important to address the 
possibility that cytopathic effects mediated by HCV infection were responsible for 
inhibiting NK cell functions. This potential mechanism was queried as we noted 
decreased cell viabi lity at high MOis with HCV (refer to Figure 3.2 B). 
Furthermore, preliminary evidence suggests HCV proteins such as NS4B (85) 
may induce or cause cytopathic effects, leading to cellular apoptosis. A recently 
discovered inhibitory receptor, TIM-3, is expressed on the surface of NK cells and 
interacts with PtdSer and Gal-9. Mengshol et a/. demonstrated high levels of 
circulating Gal-9 in the serum of individuals chronically infected with HCV (218) . 
Here we use the assay developed in Chapter 3 to assess whether inhibited NK 
cell functions is caused by HCV-infected Huh-7.5 cells or indirectly a result of 
apoptotic H uh-7 .5 cells. 
4.2 Z-VAD-FMK Treatment Has No Effect on NK Cell Cytotoxicity 
Since the apoptosis inhibitor Z-VAD-FMK is a pan caspase inhibitor, we 
wanted to determine whether Z-VAD-FMK treatment would affect NK cell-
mediated granzyme-induced caspase-dependent apoptosis of target cells . We 
assessed NK cell lysis of 51Cr-labeled K562 cells in the presence of Z-VAD-FMK 
91 
and saw no difference in percent specific lysis of labeled K562 cells in the Z-
VAD-FMK-treated assay compared with the untreated assay (Figure 4.1 A). To 
determine whether Z-VAD-FMK was able to prevent apoptosis in the Huh-7.5 cell 
line, we compared the extent of cellular apoptosis in uninfected and HCV-infected 
Huh-7.5 cells through the detection of DNA content by PI binding. As apoptosis 
is characterized by DNA fragmentation , hypodiploid cells are identified as 
apoptotic, diploid cells are classified as being in resting phase (Gap 0 and Gap 1) 
and tetraploid cells are undergoing cell division (Gap 2). Approximately 12% of 
uninfected Huh-7.5 cells were apoptotic, and 24 hour treatment with Z-VAD-FMK 
marginally reduced apoptotic cell numbers to -9% (Figure 4 .1 B). Comparably, 
PI staining indicates that -70% of the Huh-7.5 cells infected at a MOl of 4 .8 are 
undergoing apoptosis, whereas only -30% of the infected Huh-7.5 cells are 
undergoing apoptosis when treated with Z-VAD-FMK for 24 hours (Figure 4.1 B) . 
Kohafi et a/. (unpublished data) have also shown that Z-VAD-FMK treatment 
reduced Huh-7.5 apoptosis in HCV-infected Huh-7.5 cells by at least 50% when 
compared to untreated infected Huh-7.5 cells, as measured by PI staining. Thus, 
to determine whether inhibition of NK cell functions , as described in Chapter 3, 
occurs as a consequence of viral infection or from Huh-7.5 cell-induced 
apoptosis, we used Z-VAD-FMK to inhibit apoptosis and examined whether NK 
cell cytotoxicity declined , or remained intact. 
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4.3 Preventing Huh-7.5 Cell Apoptosis Does Not Restore NK Cell 
Cytotoxicity 
To assess whether the decline in NK cell cytotoxicity and cytokine 
production was the result of HCV infection of Huh-7.5 cells or Huh-7.5 cells 
undergoing apoptosis, uninfected or HCV-infected Huh-7.5 cells were treated for 
24 hours with pan caspase inhibitor Z-VAD-FMK to prevent apoptosis. NK cell 
cytotoxicity remained inhibited in the presence of Z-VAD-FMK (Figure 4.2 A) , 
indicating that apoptotic Huh-7.5 cells were not inhibiting NK cell cytotoxicity. 
These results were corroborated by the assessment of NK cell degranulation 
(CD1 07a production) via flow cytometry where we found no prevention of NK cell 
inhibition by Z-VAD-FMK treatment (Figure 4.2 B). We did, however, observe 
rescue of IFN-y production upon Z-VAD-FMK treatment (Figure 4.2 B). 
Therefore, NK cell inhibition is a direct result of HCV infection rather than an 
effect caused by the decline in Huh-7.5 cell viability. 
4.4 NK Cell Inhibition Is Not NK TIM-3-Mediated 
Recent findings suggest an inhibitory role for NK TIM-3 receptors cross-
linked by known ligands, PtdSer and Gal-9, expressed on apoptotic cells (170). 
We used an available anti-human TIM-3 antibody that had been shown to 
recognize the TIM-3 lg variable domain and block TIM-3 :Gal-9 interactions (229). 
We detected cell surface TIM-3 expression on NK cells (Figure 4.3 A) , and 
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treatment with a soluble anti-human TIM-3 antibody, which would block TIM-
3:1igand binding, did not affect NK cell cytotoxicity in a 5 hour 51 Cr release assay 
compared to IC-treated cells (Figure 4.3 B). To determine if NK cell inhibition 
was TIM-3-mediated , we performed an antibody-mediated receptor/ligand 
masking experiment. Treating NK cells with anti-TIM-3 did not prevent inhibition 
of NK cell cytotoxicity in the presence of HCV-infected Huh-7.5 cells compared 
with uninfected Huh-7.5 cells (Figure 4.3 C). Although TIM-3 is expressed on NK 
cells and may be capable of eliciting an inhibitory response, in this instance, NK 
cell inhibition is TIM-3-independent. 
4.5 Apoptotic LS1 02.9 Cells Inhibit NK Cell Cytotoxicity 
Independent of NK TIM-3 
As Ndhlovu et a/. found that NK cells express TIM-3 and provides an 
inhibitory signal (170), we decided to examine the possibility that apoptotic cells 
expressing PtdSer and/or Gal-9 could inhibit NK cell cytotoxicity in a T IM-3-
mediated mechanism. We used the anti-Fas (also known as AP0-1 or CD95)-
sensitive murine LS1 02.9 cell line to induce cellular apoptosis, then examined if 
treatment with anti-TIM-3 prevented the ability of NK cells to lyse 51 Cr-labeled 
K562 cells. We found that apoptotic LS102.9 cells (42% dead on average, 
assessed by trypan blue staining) inhibited NK cell cytotoxicity by a mean of 25 ± 
8% (SEM; p = 0.0010, Student's paired t test; n = 7) (Figure 4 .4 A). However, 
TIM-3 treatment did not rescue NK cell cytotoxicity against 51 Cr-labeled K562 
100 
cells in the presence of apoptotic LS1 02.9 cells (Figure 4.4 B) . This data 
suggests that the mechanism by which apoptotic cells inhibit NK cells in this 
assay is TIM-3 independent. 
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5 Discussion 
Through interaction with host innate and adaptive immune responses, 
HCV has evolved mechanisms to circumvent immune pressures and establish 
chronic infection. Cytokines produced by NK cells , such as IFN-y and TNF-a, 
play a synergistic role in innate and adaptive immune responses (230). Several 
studies suggest that NK cells play a role in clearance or control of HCV infection 
or associate NK cell dysfunction with HCV infection (19, 231 , 232). Here, we 
designed an assay platform to study the effects HCV-infected cells have on NK 
cells and found that direct contact with HCV-infected cells in vitro inhibited ex vivo 
NK cell cytotoxicity and cytokine production. We found that inhibition of NK cell 
cytotoxicity and cytokine production was contact-dependent with HCV-infected 
cells and appeared proportional to HCV infection levels. 
Previous studies addressing the role NK cells play in HCV infection 
focused on interactions between HCV E2 and CD81 on NK cells as a potential 
mechanism for NK cell dysfunction (211-213). These studies used recombinant 
HCV E2, cell-free HCV, or virus attached to a solid support and IL-2-stimulated 
(212) or purified NK cells (211 ). In some cases, this resulted in decreased NK 
cell cytotoxicity and cytokine production via the cross-linking of NK CD81. As a 
consequence, inhibition of NK cell functions through HCV E2:NK CD81 cross-
linking is often proposed as a means to promote HCV persistence (233-236). 
AP33, a broadly neutralizing antibody against the CD81 -bind ing site, recognizes 
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a linear epitope located between amino acid residues 412 and 423 of HCV E2 
(114, 227, 237) . We used this antibody to probe for extracellular HCV E2 
expression on Huh-7.5 cells , as well as to block HCV E2 and NK CD81 
interactions. We found no evidence for surface HCV E2 expression on HCV-
infected Huh-7.5 cells and disruption of potential HCV E2:NK CD81 interactions 
by masking HCV E2 did not prevent the decline in NK cell cytotoxicity mediated 
by HCV-infected cells . 
NK cell functions remained intact when incubated with cell-free JFHh 
HCV, providing additional evidence that the mechanism by which HCV evades 
NK cell cytotoxicity is not HCV E2 mediated , and requires direct contact with 
HCV-infected Huh-7.5 cells. Previous studies also indicated that HCV E2 
molecules, as displayed on HCV genotype 1 a or 2a virions , do not inhibit NK cell 
functions , even when used at titres exceeding HCV RNA and protein 
concentrations found in the blood of infected individuals (213). These results 
suggest that although the configuration of natural HCV E2 may support binding to 
NK CD81 , E2 as part of an intact infectious virus particle does not facilitate the 
necessary cross-linking of NK CD81 receptors to mediate an inhibitory signal 
(211 , 212). Also, though HCV E2 is able to bind host hepatocyte CD81 to 
facilitate entry, CLDN1 , OCLN , and especially SRBI are important co-receptors 
for virus infection and are not constituents of the NK cell receptor repertoire. Our 
results suggest that an HCV E2:NK CD81 interaction is not the primary cause of 
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impaired NK cell functions mediated in vitro, and likely in vivo, by HCV-infected 
cells. Also, while HCV infection of Huh-7.5 cells may cause the induction of 
antagonistic host proteins to interact with NKp30, it is possible that a viral protein 
other than E2 may cause disrupted NK cell functions. This possibility may be 
explored through the examination of NK cell functions in the presence of a stable 
cell line autonomously repl icating subgenomic RNA (NS3-NS58) . However, HCV 
virions assemble and mature through the cell secretory pathway, rather than bud 
through the cell surface. Thus, it is unlikely that viral proteins are found on the 
surface of HCV-infected cells and, therefore, are unable to interact with , and 
inhibit NK cells. 
Although blocking HCV E2:NK CD81 interactions did not rescue NK cell 
function , we did find that treating NK cells with anti-CD81 abrogated NK cell 
inhibition. Previous studies show that cross-linking NK CD81 receptors by either 
CD81 antibodies or immobilized HCV E2 blocks NK cell cytotoxicity, cytokine 
production and proliferation (211 , 212) . NK CD81 cross-linking has been shown 
to block the signaling pathway induced by CD16 engagement by reducing the 
overall level of tyrosine phosphorylation , specifically of the ~ chain and 
downstream mitogen-activated protein kinase (MAPK) and extracellular signal-
related kinase (ERK)-2 molecules (211 , 238). As CD16 and NCRs NKp30 and 
NKp46 share a conserved signaling pathway, and may also signal through ~ 
chain homo- or heterodimer adaptor proteins, the CD81 tetraspanin may also 
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negatively affect NK cell signaling through the same mechanism of reduced 
tyrosine phosphorylation of signaling substrates. The HCV-infected cell-mediated 
decline in NK cell functions could be CD81-dependent through the direct 
interaction with an antagonistic ligand, with the exception of HCV E2, on HCV-
infected Huh-7.5 cells, or regulated indirectly, through a tetraspanin:membrane-
associated receptor interaction with an antagonistic ligand up-regulated on HCV-
infected Huh-7.5 cells . 
One characteristic of the tetraspanin CD81 is its proclivity for interacting 
with partner proteins embedded in the cell membrane to form signal transduction 
complexes (239). The effect of CD81 cross-linking varies not only with cell type, 
but also with which membranous protein it interacts. Lateral interaction of CD81 
with an associated protein could either augment or impair positive or negative 
stimuli depending on the cell type (239). Predominantly, the extracellular domain, 
LEL, mediates lateral protein-protein interactions or interactions with the few 
known ligands for CD81 (reviewed in [240]). CD81 forms complexes with CD19 
and CD21 (CD19-CD21 co-receptor complex) on B cells and is thought to recruit 
this co-stimulatory complex to the B cell receptor to augment activation 
thresholds. It also associates with T cell signaling proteins CD3, CD4 and CDS 
(239). Thus, although no associated proteins have yet to be identified on NK 
cells , it is possible that CD81 laterally interacts with membrane proteins on NK 
cells to increase or decrease stimuli delivered, for example, by ligands up-
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regulated following HCV-infection. Blocking NK CD81 with anti-CD81 could 
prevent these lateral protein-protein associations and in turn modulate negative 
stimuli and reduce or eliminate the inhibition of NK cell functions. 
The extent to which tetraspanins contribute to immune interactions is 
currently unknown ; the paucity of mechanistic information likely stems from the 
complexity of their associations. The cytoplasmic regions of tetraspanins 
organize extracellular stimuli through association with intracellular signaling 
molecules to facilitate signaling cascades (reviewed in [240]). However, there 
are indications that tetraspanins are also involved in cytoskeleton rearrangement 
in both T and NK cells . In fact, Crotta et a/. suggest that inhibition of NK cell 
cytotoxicity and cytokine production through CD81 is mediated by cytoskeletal 
rearrangement (238). Coffey eta/. further show that engaging CD81 leads to the 
phosphorylation of ezrin (at Y353), a protein which bridges membrane proteins to 
the actin cytoskeleton to allow membrane reorgan ization for cellular signaling 
(241 ). Our preliminary results could not determine a role for ezrin as a 
mechanism by which CD81 affects NK cell functions , and propose that the 
negative signaling cascade stimulated by direct contact with HCV-infected Huh-
7.5 cells may be augmented by lateral interactions between CD81 and an as yet 
unidentified partner receptor. However, further studies regarding the importance 
of ezrin and cytoskeletal rearrangement for the control of NK cell lytic capabilities 
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may be warranted , based upon studies regarding T cell receptors (TCR) 
discussed below. 
Although we believed that HCV infection of the Huh-7.5 cells is 
responsible for disrupted NK cell functions , we noted decreased Huh-7.5 cell 
viability at high levels of infection with HCV. Thus, it was necessary to determine 
whether cytopathic effects on Huh-7.5 cells from HCV infection impacted NK cell 
functions. Although treating Huh-7.5 cells with pan caspase inhibitor, Z-VAD-
FMK, blocked -50% of the Huh-7.5 cells from undergoing apoptosis at a high 
MOl , this treatment did not prevent the decline in NK cell cytotoxicity. Thus, the 
negative effect that Huh-7.5 cells have on NK cell functions is HCV-dependent 
while independent of HCV-induced cytopath ic effects. To further confirm that 
cytopathic effects were not eliciting down-regulated NK cell functions , we 
assessed whether the TIM-3 NK cell receptor was responsible for restrained NK 
cell cytotoxicity. PtdSer is implicated as a TIM-3 ligand and is expressed at the 
outer leaflet of the plasma membrane upon initiation of apoptosis (175). TIM-3 is 
expressed on NK cells and, when engaged and cross-linked , suppresses NK cell 
cytotoxicity and reduces anti-viral properties in chronic infection (171 ). The 
mechanism by which this occurs is unknown, as this receptor lacks any known 
inhibitory motifs (170-173). Consequently, disruption of NK cell TIM-3:1igand 
interactions should perturb any inhibitory effect TIM-3 may have on NK cells in 
the context of HCV-infected Huh-7.5 cells. We did not observe abrogation of the 
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inhibition of NK cell cytotoxicity upon blockade of TIM-3 receptors. However, 
further exploration into this mechanism of NK cell inhibition is necessary to 
eliminate this possibility. Of note, high levels of circulating Gal-9 occurs in the 
serum of chronically HCV-infected individuals (218) and expression levels of 
neither Gal-9 nor PtdSer were explored in the context of uninfected and HCV-
infected Huh-7.5 cells. Additionally, incubation of ex vivo NK cells with uninfected 
or HCV-infected Huh-7.5 cells in the presence of recombinant soluble TIM-3 
glycoprotein, which competes for TIM-3 ligands, can be used to address the 
possibility that the TIM-3 antibody used in this study did not mask the epitope 
recognized by either Gal-9 or PtdSer. 
On the basis that apoptotic Huh-7.5 cells could affect NK cell cytotoxicity, 
we also examined whether other apoptotic cells had any influence on NK cell 
function . We determined that Fas receptor (FasR)-mediated induction of 
apoptosis in the murine LS1 02.9 cell line reduced NK cell cytotoxicity. However, 
down-regulated NK cell cytotoxicity was independent of TIM-3, as blocking TIM-3 
receptors did not rescue NK cell cytotoxicity. Additional experiments, including 
those outlined above, are needed to effectively eliminate TIM-3 signaling as a 
means by which NK cell inhibition, in the presence of apoptotic cells , occurs. An 
alternative means by which apoptotic cells could influence NK cell cytotoxicity is 
through the PBMC cytokine microenvironment in vitro . Monocytes release IL-1 0 
and also immunosuppressive cytokine, transforming growth factor (TGF)-f3 , upon 
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exposure to apoptotic cells (reviewed in [242]). Although IL-1 0 has stimulatory 
effects on NK cells (reviewed in [243]) , especially in the presence of IL-12 or IL-
18 (244), TGF-[3 attenuates immune responses to eliminate self-reactivity, 
including NK cell responses (245, 246). In vitro studies showed that TGF-[3 
decreased expression of activating receptors and their respective adaptor 
proteins on NK cells, corresponding with reduced NK cell functions, however, NK 
cell activity could be restored by treatment with anti-TGF-[3 antibody (247, 248). 
Thus, further examination to assess whether apoptotic cells may affect 
monocytes, T cells or 8 cells in the PBMC microenvironment, which , in turn 
impact NK cell cytotoxicity, would be beneficial. 
In order to determine the manner in which NK cell cytotoxicity is down-
regulated in the presence of HCV-infected Huh-7.5 cells , we probed for 
differences in NK cell receptor expression when incubated with HCV-infected, 
compared to uninfected , Huh-7.5 cells and probed HCV-infected Huh7.5 cells for 
NK cell ligands. Nattermann eta/. demonstrated up-regulated HLA-E expression 
on hepatocytes during chronic infection , as HLA-E can be stabilized and up-
regulated by HCV core peptide (aa35-44) (228) . Although HLA-E is known to be 
a ligand for inhibitory NK receptor NKG2AICD94, we and others did not observe 
increased expression of HLA-E on HCV-infected Huh-7.5 cells (215). Despite 
inhibition of ADCC, CD16 expression levels were unaltered on NK cells exposed 
to HCV-infected cells. A previous study by Yoon et a/. showed that NK cell 
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cytotoxicity and IFN-y production were reduced following 18 hour co-culture with 
HCV-infected Huh-7.5 cells, and also noted a decline in NKp30 and NKG2D cell 
surface expression on NK cells (215) . However, we did not observe a reduction 
in NKG2D expression on NK cells after 5 hours of incubation with infected cells. 
NKp30 was the only NK receptor we examined with decreased cell surface 
expression. These in vitro data corroborate the ex vivo observation of reduced 
circulating NKp30-expressing NK cells in individuals with chronic HCV infection 
(21 0). Interestingly, CD16 and NKp30 can associate with the same ~ chain 
adapter molecule, which mediates intracellular signaling and ultimately leads to 
NK cell cytokine secretion , cytotoxicity and ADCC through CD16 (249). 
The ~ chain is composed of a short, extracellular domain consisting of nine 
amino acids and an intracellular domain containing ITAMs. Upon ITAM 
phosphorylation by lymphocyte-specific protein tyrosine kinase (Lck) , the SYK 
family kinases, spleen tyrosine kinase (Syk), and ~ chain associated protein 
kinase of 70 kDa (ZAP70) are recruited. This recruitment ultimately leads to ERK 
phosphorylation and subsequent NK cell cytotoxicity and cytokine production 
(249-252) (Figure 1. 7). Although the cytoskeleton is essential for the structural 
support of a cell, it is also an important physical support for the enzymatic 
processes governing cellular signaling, linking the extracytoplasmic stimulus to 
the intracellular signaling cascade (253, 254). Studies of ~ chain involvement 
with TCRs have shown that the ~ chain links approximately one third of 
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expressed TCRs to the actin cytoskeleton and may also stabilize extracellular 
TCR expression (253, 254) . Based on these findings that the ~ chain links the 
actin cytoskeleton in T cells , and the role CD81 has in actin redistribution via 
ezrin phosphorylation in order to activate , or inhibit T and NK cells, respectively 
(241 ), we can speculate that an altered pattern of actin distribution is an aspect of 
the underlying mechanism which inhibits NK cell functions through direct contact 
with HCV-infected Huh-7.5 cells. 
Our data show impairment of NK cell cytotoxicity and cytokine production 
in the presence of HCV-infected Huh-7.5 cells. This corresponds with down-
regulation of the NCR NKp30, and increased binding of an NKp30-lgG1 Fey 
fusion protein to the surface of HCV-infected cells . An antagonistic NKp30 ligand 
induced on HCV-infected cells could inhibit NK cell-mediated immune 
mechanisms and favour progression to chronic HCV infection in a manner similar 
to that observed for HCMV. Arnon et a/. demonstrated a direct antagonistic 
interaction between HCMV tegument protein pp65 and NK cell activating receptor 
NKp30 that reduced NK cell cytotoxicity through disassociation of the ~ chain 
adaptor protein from NKp30 (204) . 
Antagonism of the ~chain associated with the NKp30 receptor, through an 
interaction with a putative NKp30 ligand , can abrogate activating signal 
transduction through the Lck-7ERK signaling pathway (249). Further studies to 
determine this putative antagonistic ligand for the NKp30 receptor, as well as its 
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binding site on NKp30 are necessary. Recently, the extracellular domain of 
NKp30 was crystallized and its structure determined (255). Although many 
ligands for NKp30 have been identified , the physiological significance of these 
ligand:NKp30 receptor interactions remain to be determined (201 , 204, 256-259) . 
Interestingly, NKp30 exhibits structural homology to programmed cell death 
protein 1 (P0-1 ), cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and 
C028 receptors , which all recognize the N-terminal region of their respective B7 
family ligands (260-262). Thus, based on structural homology with the C028 
family of receptors (C028, CTLA-4, P0-1 ), NKp30 may recognize other as yet 
unidentified homologues of the B7-H6 ligand (201, 202, 255). It should be noted, 
however, that these structural studies only considered the extracellular binding 
domain of NKp30 and did not take into account the remaining domains 
comprising NKp30. 
NKp30 possesses an extracellular ligand binding domain (LBO) , a 
transmembrane domain (TMO) to which adaptor molecules (i.e. ~ homodimers) 
bind , and a short, 33 amino acid cytoplasmic tail (193). Recently, Hartmann eta/. 
discovered that the flexible stalk domain that connects the LBO to the TMO is N-
linked glycosylated. The extent to which th is domain is glycosylated not only 
impacts the affinity of ligand:receptor binding , but may also regulate NK cell 
cytoxicity via ~chain signaling (179). This study goes on to show that the binding 
of B7-H6 to the ligand binding pocket of NKp30 is dependent on N-linked 
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glycosylation at amino acid 42 (N42) , and efficient intracellular signaling is 
contingent upon glycosylation of both N42 and N68 (179). These layers of 
complexity surrounding NKp30 and the transduction of extracellular stimulus to 
intracellular signals should be considered for the elucidation of an antagonistic 
ligand for NKp30 on HCV-infected Huh-7.5 cells. 
Although we note increased expression of the putative NKp30 ligand on 
the surface of HCV-infected Huh-7.5 cells in vitro , the Huh-7.5 cell line is derived 
from transformed primary human hepatoma cells, thus, further in vivo or ex vivo 
study of primary hepatocytes to determine whether this is a genuine physiological 
effect are warranted. For instance, human cancers express high levels of 87 -H1 
protein , whereas human tumour cell lines have lowered B7-H1 expression , 
perhaps caused by the lack of tumour microenvironment or altered molecular 
profiles (reviewed in [263]). Based upon the structural homology of the NKp30 
receptor with the C028 receptor family, which recognize the 87-family of 
proteins, it is possible that a 87 -family protein could be interacting with , and 
inhibiting, NK cell functions through NKp30 in our in vitro system (201 , 202, 255) . 
As both 87 -H 1 [also referred to as programmed cell death ligand 1 (PO-L 1) or 
CD274] and B7-H4 (also referred to as B7S1 or B7x) ligands provide inhibitory 
signals through their interacting receptors , these ligands will be discussed in brief 
with respect to HCV infection and their expression on tumour cells (reviewed in 
[263]). 
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Several studies demonstrated high levels of inhibitory 87 -family 
molecules, 87-H1 and 87-H4, which are known to contribute to T cell immune 
evasion, on human cancer cell lines (reviewed in [264, 265]). Increased 
expression of inhibitory 87-family molecules on the human hepatoma Huh-7.5 
cell line could potentially explain low levels of direct Huh-7.5 cell lysis by NK cells 
in vitro (data not shown), contingent on an inhibitory 87 -family molecule:cognate 
NK cell receptor interaction. Primary hepatocytes constitutively express 87-H1 at 
low levels, however, 87 -H 1 expression is enhanced upon viral infection (266). 
Also, it has been shown that high levels of inhibitory 87-family ligand expression 
(87-H1 and 87-DC) correlated with chronic liver inflammation in HCV-infected 
individuals (267) . Thus, infection of human hepatoma Huh-7.5 cells with HCV 
could have a compounding effect on the expression of stress-induced inhibitory 
87-family ligand expression and may provide an antagonistic ligand for NKp30. 
Not only would this perturb immune modulation of HCV-infected (or cancerous) 
cells by T cells through PD-1 , but could also play a dual role in the modulation of 
cytotoxic NK cell functions; the latter remains to be determined. Recently, Zhao 
et a/. characterized a human endogenous retrovirus long terminal repeat-
associating protein 2 (HHLA2) as a member of the 87 family of proteins that 
binds to a putative CD4+ and cos+ T cell receptor, inhibiting cytokine production 
and cellular proliferation (268) . Determining an antagonistic NKp30 ligand of host 
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or viral origin on HCV-infected cells could provide new insights as to the 
pathogenesis of this viral infection. 
There are many mechanistic possibilities by which HCV-infected Huh-7.5 
cells inhibit NK cell cytotoxicity and cytokine production . Based upon published 
literature and our own observations , we reason that inhibited NK cell functions 
stems from the interaction of NKp30 with an inhibitory 87 family protein , which is 
induced on Huh-7.5 cells upon HCV infection. This ligand may either interact 
directly with the NKp30 receptor, or interact with and disrupt the ~ chain adaptor 
protein in a manner similar to HCMV pp65 . Ultimately, downstream NK cell 
signaling is affected resulting in inhibited cytotoxicity and cytokine production . 
Interaction of an inhibitory 87 family ligand with NKp30 can also account for 
disrupted ADCC noted through CD16, as these receptors can have a common 
adaptor molecule (i.e. ~ chain homo or heterodimers) and share a concerted 
signaling pathway. CD81 could contribute to NK cell signaling in the same 
manner as it does with B and T cell co-receptors, through its lateral interaction 
with NKp30. Finally, as the actin cytoskeleton rearranges to allow release of 
cytotoxic granules, engagement of NKp30 with a putative antagonistic ligand and 
its potential interaction with CD81 can ultimately lead to an alteration of actin 
cytoskeleton , thereby depressing granzyme release. 
Evidence is emerging that indicates NK cells play an important role in host 
defenses against virus infection and tumour progression. Although our 
117 
understanding of T cells has led to the development of therapies to suppress or 
enhance T cell functions , NK cell-based immunotherapy has been delayed, as 
the mechanisms involving NK cell activation and inhibition as well as knowledge 
of the cellular distribution of NK cells and in vivo homing to tissues remained 
undefined until the late 1990s (269-271 ). Before we can determine if NK cells 
can be modified for viral therapy, further insight into their complete role in HCV 
infection must be achieved. It is important to establish why the combination of 
inhibitory KIR2DL3 with HLA-C group 1 alleles is beneficial for the spontaneous 
clearance of HCV infection (19, 20, 272). In the context of HIV infection , Alter et 
a/. describe attenuation of HIV-1 replication in the presence of KIR2DL2+ NK 
cells, however, HIV-1 evades this mechanism of NK cell recognition by selecting 
viral variants with amino acid polymorphisms that augment the binding of 
inhibitory KIRs to infected CD4+ T cells (17) . Thus, these data convey that 
enhanced NK cell activity contributes to the control of viral infection , and that 
viruses can evade this immune response through the rapid emergence of 
variants, which can escape stimulatory, and enhance inhibitory, KIR recognition . 
Inhibitory KIR genes can affect NK cell responses to viral infections through KIR 
education (273) , a phenomenon that gives plasticity to a once-rigid theory for NK 
cell responsiveness. Our data adds to the increasing evidence that NK cells play 
a role in the initial control of viral infections and provides insights into the basic 
biology of NK cells , since HCV-mediated attenuation of activating receptor 
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(NKp30) expression can impact NK cell responsiveness. Future antiviral or 
cancer therapy may follow a more extensive understanding of functionally distinct 
NK cell subsets. 
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6 Future Directions 
As discussed in Chapter 5, the initial focus of future research in this area 
should involve elucidating the antagonistic NKp30 ligand up-regulated on HCV-
infected Huh-7.5 cells . In addition , determining the NKp30 ligand-binding domain 
or the association of the putative NKp30 ligand with an adaptor molecule 
associated with NKp30 would be beneficial. Further, the impact this ligand 
binding to NKp30 on downstream signaling cascades or cytoskeletal 
redistribution should be probed. Although ADCC was inhibited, it would be 
interesting to determine the link between down-regulated NKp30 expression and 
CD16 dysfunction. Finally, this established assay could further be used to probe 
activity of NK cells from HCV positive individuals compared to healthy controls. 
The data obtained from clinical samples could determine whether altered NKp30 
expression is an immediate or lasting effect in the context of HCV infection. 
Furthermore, this assay platform could also be beneficial for the study of NK cell 
functions in the context of other adherent tissue culture models of virus infection, 
such as HCMV. 
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